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Resumo
Hoje em dia,  especialmente  na área  biomédica,  os  dados contêm milhares  de variáveis  de fontes
diferentes e com apenas algumas instâncias ao mesmo tempo. Devido a este facto, as abordagens da
aprendizagem automática enfrentam dois problemas, nomeadamente a questão da integração de dados
heterogéneos e a seleção das características.  Este trabalho propõe uma solução eficiente para esta
questão e proporciona uma implementação funcional da metodologia híbrida. A inspiração para este
trabalho veio do desafio proposto no âmbito da competição  AstraZeneca-Sanger Drug Combination
Prediction DREAM Challenge em 2016, e da solução vencedora desenvolvida por Yuanfang Guan.
Relativamente a motivação do concurso, é observado que os tratamentos combinatórios para o cancro
são mais eficientes do que as terapias habituais de agente único, desde que têm potencial para superar
as desvantagens dos outros (limitado espetro de ação e desenvolvimento de resistência). No entanto, o
efeito combinatório de drogas não é obvio, produzindo possivelmente o resultado aditivo, sinérgico ou
antagónico. Assim, o objetivo da competição era prever in vitro a sinergia dos compostos, sem ter
acesso aos dados experimentais da terapia combinatória. No âmbito da competição foram fornecidos
ficheiros de várias fontes, contendo o conhecimento farmacológico tanto experimental como obtido
de ajustamento das equações, a informação sobre propriedades químicas e estruturais de drogas, e por
fim,  os  perfis  moleculares  de  células,  incluindo  expressão  de  RNA,  copy  variants,  sequência  e
metilação de DNA. O trabalho referido envolveu uma abordagem muito bem sucedida de integração
dos dados heterogéneos, estendendo o modelo com conhecimento disponível dentro do projeto The
Cancer Cell Line Encyclopedia, e também introduzindo o passo decisivo de simulação que permite
imitar  o  efeito  de  terapia  combinatória  no  cancro.  Apesar  das  descrições  pouco  claras  e  da
documentação da solução vencedora ineficiente, a reprodução da abordagem de Guan foi concluída,
tentando ser o mais fiel possível. A implementação funcional foi escrita nas linguagens R e Python, e o
seu desempenho foi verificado usando como referência a matriz submetida no concurso. Para melhorar
a  metodologia,  o  workflow de  seleção  dos  características  foi  estabelecido  e  executado  usando  o
algoritmo  Lasso.  Além  disso,  o  desempenho  de  dois  métodos  alternativos  de  modelação  foi
experimentado,  incluindo  Support  Vector  Machine  and  Multivariate  Adaptive  Regression  Splines
(MARS). Várias versões da equação de integração foram consideradas permitindo a determinação de
coeficientes aparentemente ótimos. Como resultado, a compreensão da melhor solução de competição
foi  desenvolvida  e  a  implementação  funcional  foi  construída  com  sucesso.  As  melhorias  foram
propostas e no efeito o algoritmo SVM foi verificado como capaz de superar os outros na resolução
deste problema, a equação de integração com melhor desempenho foi estabelecida e finalmente a lista
de  75  variáveis  moleculares  mais  informativas  foi  fornecida.  Entre  estes  genes,  poderiam  ser
encontrados possíveis candidatos de biomarcadores de cancro. 
Palavras Chave: aprendizagem automática, modelo preditivo, seleção de características, integração
de dados

Abstract
Nowadays, especially in the biomedical field, the data sets usually contain thousands of multi-source
variables and with only few instances in the same time. Due to this fact, Machine Learning approaches
face two problems, namely the issue of heterogenous data integration and the feature selection. This
work proposes an efficient solution for this question and provides a functional implementation of the
hybrid  methodology.  The  inspiration  originated  from  the  AstraZeneca-Sanger  Drug  Combination
Prediction DREAM Challenge from 2016 and the winning solution by Yuanfang Guan. Regarding to
the motivation of competition, the combinatory cancer treatments are believed to be more effective
than  standard  single-agent  therapies  since  they  have  a  potential  to  overcome  others  weaknesses
(narrow spectrum of  action and development  of  the  resistance).  However,  the  combinatorial  drug
effect is not obvious bringing possibly additive, synergistic or antagonistic treatment result. Thus, the
goal  of  the  competition  was  to  predict  in  vitro  compound  synergy,  without  the  access  to  the
experimental combinatory therapy data. Within the competition, the multi-source files were supplied,
encompassing the pharmacological knowledge from experiments and equation-fitting, the information
on chemical  properties  and  structure  of  drugs,  finally  the  molecular  cell  profiles  including  RNA
expression, copy variants, DNA sequence and methylation. The referred work included very successful
approach of heterogenous data integration, extending additionally the model with prior knowledge
outsourced from The Cancer Cell Line Encyclopedia, as well as introduced a key step of simulation
that allows to imitate effect of a combinatory therapy on cancer. Despite unexplicit descriptions and
poor documentation of the winning solution, as accurate as possible, reproduction of Guan’s approach
was accomplished. The functional implementation was written in R and Python languages, and its
performance was verified using as a reference the submitted in challenge prediction matrix. In order to
improve the methodology feature selection workflow was established and run using a Lasso algorithm.
Moreover, the performance of two alternative modeling methods was experimented including Support
Vector Machine and Multivariate Adaptive Regression Splines (MARS). Several versions of merging
equation were considered allowing determination of apparently optimal coefficients. As the result, the
understanding of the best challenge solution was developed and the functional implementation was
successfully constructed. The improvements were proposed and in the effect the SVM algorithm was
verified  to  surpass  others  in  solving  this  problem,  the  best-performing  merging  equation  was
established, and finally the list of 75 most informative molecular variables was provided. Among those
genes, potential cancer biomarker candidates could be found.
Keywords: machine learning, predictive model, feature selection, data integration

Resumo Alargado
Hoje em dia,  especialmente  na área  biomédica,  os  dados contêm milhares  de variáveis  de fontes
diferentes e com apenas algumas instâncias ao mesmo tempo. Devido a este facto, as abordagens da
aprendizagem automática enfrentam dois problemas, nomeadamente a questão da integração de dados
heterogéneos e a seleção das características.  Este trabalho propõe uma solução eficiente para esta
questão e proporciona uma implementação funcional da metodologia híbrida. A inspiração para este
trabalho veio do desafio proposto no âmbito da competição  AstraZeneca-Sanger Drug Combination
Prediction DREAM Challenge em 2016, e da solução vencedora desenvolvida por Yuanfang Guan.
Relativamente a motivação do concurso, é observado que os tratamentos combinatórios para o cancro
são mais eficientes do que as terapias habituais de agente único, desde que têm potencial para superar
as desvantagens dos outros (limitado espetro de ação e desenvolvimento de resistência). No entanto,
o  efeito  combinatório  de  drogas  não  é  obvio,  produzindo  possivelmente  o  resultado  aditivo  (se
o resultado é equivalente aos efeitos somados de dois medicamentos), sinérgico (quando a resposta
é  exagerada e  superior  dos  efeitos  aditivos  de dois  produtos  químicos)  ou  antagónico  (com uma
resposta inferior do efeitos somados do par de drogas). Assim, o objetivo da competição era prever
in vitro a sinergia dos compostos, sem ter acesso aos dados experimentais da terapia combinatória.
No  âmbito  da  competição  foram fornecidos  ficheiros  de  várias  fontes,  contendo o  conhecimento
farmacológico tanto experimental  como obtido  de ajustamento das equações,  a informação sobre
propriedades químicas e estruturais de drogas, e por fim, os perfis moleculares de células, incluindo
expressão de RNA, copy variants, sequência e metilação de DNA. O trabalho referido envolveu uma
abordagem muito bem sucedida de integração dos dados heterogéneos, estendendo o modelo com
conhecimento disponível dentro do projeto The Cancer Cell Line Encyclopedia. No entanto, os dados
moleculares são inúteis a menos que sejam simulados sob a droga, imitando o efeito de uma terapia
combinatória em células. Yuanfang Guan propôs uma abordagem baseada no conhecimento disponível
na base de dados Functional Networks of Tissues in Mouse (FNTM) e resumida no ficheiro externo
contendo informações sobre as rede funcionais entre os  genes  e a probabilidade destas conexões.
A ideia  principal  era  alterar  cada  estado original  atribuído  às  células  cancerosas,  de  acordo com
a probabilidade de ligação entre dois genes:  o gene em consideração e o gene alvo para a droga
aplicada.  De  acordo  com  a  implementação  original,  todas  as  fontes  moleculares  foram  filtradas
e  exclusivamente  o  conhecimento  relacionado  com  o  conjunto  dos  alvos  foi  considerado.  Para
produzir as previsões finais, foram construídos seis modelos: dois globais de dados moleculares e de
monoterapia,  um químico,  um contando ficheiros,  e  mais  dois  locais  de  dados  moleculares  e  de
monoterapia. Os nomes deles indicam a fonte de dados utilizada na construção de vetores de variáveis.
Posteriormente, as previsões obtidas de todos os modelos foram integradas usando média ponderada.
Para determinar a ocorrência do efeito sinérgico para a combinação específica de par de drogas e da
célula,  as  previsões  produzidas  foram  comparadas  com  a  média  total  calculada  para  todas
as instâncias. O efeito benéfico é esperado nos casos que representam o valor normalizado da sinergia
superior  da  média  global.  Apesar  das  descrições  pouco  claras  e  da  documentação  da  solução
vencedora ineficiente, a reprodução da abordagem de Guan foi concluída, tentando ser o mais fiel
possível. A implementação funcional foi escrita nas linguagens R e Python, e o seu desempenho foi
verificado usando como referência a matriz submetida no concurso. Devido ao facto que os processos
computacionalmente envolvidos na manipulação de dados moleculares foram intensos, uma filtração
adicional  dos  dados  foi  realizada.  O  objetivo  era  reduzir  o  número  de  variáveis  selecionando
unicamente  as  características  informativas  e  relevantes.  Baseando  na  informação  contida
na plataforma IntOGen, as mutações foram limitadas exclusivamente às localizadas nos oncogenes.
A base de dados  The Copy Number Variations in Disease foi usada para mapear genes de cancro
sensíveis à dosagem e para selecionar os CNVs relevantes. Embora eficaz na redução do tamanho, este
passo de filtração tem o poder elevado de interferir com os dados porque limita o espaço das variáveis
ao conhecimento já bem estabelecido. Assim,  a inferência de potenciais correlações ou implicações
está  inibida.  Após  o  desenvolvimento  da  implementação  funcional,  a  precisão  e  fidelidade  da
reprodução foram estimadas verificando o desempenho usando como referência a matriz de previsões
submetida no concurso. Esta proeza permitiu o estabelecimento de uma base e a definição de pontos
fracos do método, que no resultado indicou direções de melhoramento. Uma vez que o número de
variáveis moleculares foi um desafio real na manipulação, processamento e interpretação, foi decidido
realizar a seleção de características.  Ao contrário da filtração anterior, esse método abre um espaço
para a inferência dos novos padrões e conexões. A importância e a relevância de uma variável são
estimadas baseando nos dados experimentais que refletem o funcionamento de um sistema biológico
inteiro e possivelmente nova compreensão pode ser surgir. Após várias tentativas, o workflow final foi
estabelecido usando um algoritmo chamado Lasso. Em primeiro lugar, para cinco fontes de dados
moleculares  (exceto  metilação  devido  ao  processamento  altamente  intenso),  os  modelos  foram
preparados  com um parâmetro  λ  indefinido,  permitindo a  observação do  comportamento  do  erro
quadrático médio (Mean Square Error,  MSE) em função de lambda.  A inspeção visual  de gráfico
permitiu a estimativa de λ correspondente ao minimo valor de MSE. Seguindo essa abordagem, para
cada uma das fontes,  o parâmetro foi  estimado separadamente.  Voltou-se construir  os modelos de
lasso, mas desta vez com λ definido e em 60 iterações. Para cada fonte de dados moleculares foram
selecionadas  as  variáveis  com frequência  de  ocorrência  superior  de  30  em total  das  60  corridas
e posteriormente foram todas incluídas numa única lista. O passo inicial foi repetido, mas desta vez
exclusivamente para  as características  pré-selecionadas.  Encontrando o parâmetro lambda máximo
para o qual o número das variáveis é igual ou inferior a 60, realizou-se uma seleção final, extraindo
apenas  aquelas  instâncias  que  entram  no  modelo  com  tal  λ  definido.  Para  verificar  se  os  RFs
originalmente aplicados são verdadeiramente o método de preferência para este conjunto de dados,
dois  outros  algoritmos  de  modelação  foram  testados:  Support  Vector  Machine  and  Multivariate
Adaptive  Regression  Splines  (MARS).  Uma  vez  que  não  havia  qualquer  tipo  de   referência  ou
evidência  que  justificava  a  forma  de  combinação  dos  modelos  separados  criados  ao  longo  da
implementação,  foram  testadas  várias  versões  da  mesma  equação  de  integração,  permitindo
a determinação dos coeficientes aparentemente ótimos. Para tornar a avaliação de implementação final
mais confiável, foram usados como referência os valores de sinergia verdadeiras (em vez de previstas
por Yuanfang Guan). Formou-se novos conjuntos de treinamento e teste, a partir dos dados conhecidos
disponíveis no âmbito de concurso. Os subconjuntos reconstruíram as circunstâncias de modelação
originais, o que na prática significa que  eles foram totalmente disjuntas nos pares de drogas (como os
originais) e foram equilibrados por tamanho contendo, respetivamente 30% e 70% de informação.
Além disso, a matriz binária de predições foi melhorada e foi feita uma distinção entre 'sem sinergia'
e 'dados indisponíveis', atribuindo valores respetivamente '0' e 'NA'. Isto garantiu que a avaliação foi
realizada exclusivamente nas instâncias de teste, impedindo a excessiva representação de observações
verdadeiras negativas, como aconteceu durante a avaliação da implementação base. Como resultado,
ao  longo  deste  trabalho,  a  compreensão  da  melhor  solução  de  desafio  foi  desenvolvida
e  a  implementação  funcional  foi  construída  com  sucesso.  Foram  propostas  as  melhorias  na
metodologia, em relação à seleção de características, modelação e aos passos de integração. No efeito,
foi  fornecida  a  lista  de  75  variáveis  moleculares  de  toda  informação  sobre  expressão,  mutações
e CNVs. Entre estes genes, poderiam ser encontrados possíveis candidatos a biomarcadores do cancro,
merecendo mais atenção e exploração. O algoritmo SVM foi verificado a superar os RFs na resolução
do problema de competição, e a equação de integração com o melhor desempenho foi estabelecida.
A implementação final tornou-se um exemplo da abordagem que fornece uma solução eficiente para
os problemas de aprendizagem automática com os dados heterogéneos de muitas variáveis e poucas
instâncias.
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1. Introduction
1.1. Problem
The aim of this work is to propose an efficient approach that provides a solution for machine learning
problems with thousands of multi-source variables and with only few instances in the same time. Thus,
there  are  two  separate  but  equally  interesting  aspects:  heterogenous  data  integration  and  feature
selection. 
With the recent advance in technologies, production and acquisition of a data is not an issue any more.
Every day, every minute, continuously there are giga-bytes, tera-bytes of diverse information being
generated [1]. The matter is how to turn it all efficiently to an useful knowledge that would truly bring
a change to the world. The very first step on that pathway is a data integration that aims merging of the
data provided by different sources, having particular structures and manner of organization, finally
holding an information on various subjects  [2]. The field of biomedical research is one of the cases
which is abundant in data encompassing genomics, transcriptomics, metabolomics, proteomics and
clinical records, and the efficient tools making a use of those are needed [3].
Recently a  special  attention has  been given to the  research on pattern recognition in  a data  with
redundant  and potentially irrelevant  information among small  set  of  samples  [4].  All  the methods
targetting this challenge has a principal idea in common, that is the identification and opting for a
subset  of  predictors  [5][6].  The advantages of feature selection are numerous and unquestionable:
easing the visual representation and interpretation of data, facilitating its handling and storing, turning
training and querying less time- and resources-consuming, and finally achieving a better performance
through effective managing with the dimensionality [7]. The approaches widely proposed in scientific
literature differ in the focus, giving more attention to some aspects than to another, and one need to
select a solution according to the particular objectives and the problems faced with. The main question
to answer is to identify which features shall be selected: relevant or useful, because those, surprisingly,
are  not  necessarily  equal  and  it  is  crucial  to  understand  the  difference  [8][9].  The  set  of  useful
variables  includes  only those which build good predictions,  while in  contrast,  the list  of  relevant
variables  contains  factors  highly correlated with the  response that  usually  brings  the  suboptimal
result. 
The  inspiration  to  the  present  work,  originated  from  the  AstraZeneca-Sanger  Drug  Combination
Prediction DREAM Challenge from 2016 and the winning solution provided by an excellent scientist:
Yuanfang  Guan.  Launching  the  competition,  several  institutions  joined  their  efforts  and  ideas,
including  AstraZeneca, European Bioinformatic Institute, the Sanger Institute, Sage Bionetworks and
finally DREAM community [10]. The referred the best submission included very successful approach
of heterogenous data integration encompassing among others chemical, experimental and multi-source
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molecular data on RNA expression, copy variants, DNA sequence and methylation. Additionally, the
author introduced a crucial simulation step that modeled the profiles of cell lines under the application
of particular treatments.
Regarding to feature selection, the step was proposed and included within the optimization procedures.
Beside the improvement of performance, this process allowed identification of potential molecular
biomarkers that could be important in predicting the synergy under the treatment. 
The acquired knowledge was also hoped to bring an insight into determination of the behavior and
outcome of combinatory treatments with new compounds or new combinations and with extended
application to various diseases. The drug-pairs are already widely used as therapeutics in  hepatitis C
virus, malaria, pneumonia, asthma and others [11]. Their potential is still not evaluated in number of
clinical cases for example in neuropathologies or mood disorders.
1.2. The wisdom of crowds
The quotation above is wrong, as proved by Surowiecki in his book [12]. The knowledge that comes
from a community is much more powerful than an individual idea. This concept became a principle of
any crowdsourcing effort, likewise of the initiator DREAM Challenge. Its objective is to  examine a
biological  and medical  questions by collective approach  [13]. Each year a number of problems is
brought  to  the  scientific  community  that  joins  the  researches  from  different  environments  and
backgrounds like academical, technological, biotechnological or pharmaceutical, including companies,
non-profit organization etc  [14]. The participants are always provided with datasets on which they
develope  their  methodologies,  and  additionally  with  the  common  benchmarks  and  standardized
performance metrics that allow the evaluation and comparison after the realized submissions [15].
Despite of the impressing advance in medicine and pharmacology, cancer still continues to win many
fights for human lives. This is uncontrolled intense growth of cells driven by genetic factors that are
interconnected in complex network of interactions. The therapies commonly applied usually target an
individual  cancer  line  and  are  not  able  to  effieciently  control  the  tumor  development  [16].  The
combinatory cancer treatments are believed to be more effective than standard single-agent therapies
since they have a potential to overcome others weaknesses. Mainly, they shall present broaden range
of activity, targeting simultaneously more than a single protein or biological pathway, and they should
bring a solution to a resistance gain during the medication. This boost of the anticancer activity must
be  achieved  obviously  without  consequences  of  increased  toxicity  [17].  While  designing  such  a
therapy, the very first property to be taken into consideration shall be a combinatorial drug effect that
eventually can be:
1) Additive, if the final result is equivalent to summed outcomes of each drug;
2)  Synergistic,  when the  response  is  exaggerated  and  beyond the  additive  effects  of  two
chemicals;
3) Antagonisitic, with a reply beneath the summed effects of drug pair.
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“No one in this world, so far as I know, has ever lost money by underestimating the intelligence of the 
great masses of the plain people.” 
H. L. Mencken
Although  the  concept  is  simple  and  highly  promising,  it  is  an  issue  to  accurately  predict  the
combinatory  effect  of  drugs  due  to  the  lack  of  explicit  understanding  of  underlying  interaction
mechanisms [18]. Thus, the assessment is mainly built on experimental measurements. However, in
practice and in laboratory it turns very complicated due to a very large number of possibilities of drug
combinations and their dosages. For this reason, the predictive models that would bring a support, are
urgently sought for and became a problem brought by a DREAM to a research community.
The shared idea that united a board of referred already challenge, was to contribute to an expansion of
knowledge on synergy of drugs. Thus, the goal of competition was an exploration of crucial patterns
that  drive  the  combinatory  therapies  of  a  cancer  patients,  leading  to  a  particular  response.  The
participants were asked to determine a drug combination effects on a experimental data from mono-
therapies.  The  main issue –  how to  infer  a  knowledge on  the  drug-pair  synergy,  basing  on dose
response observed for single compounds, was solved by organizers. They proposed a method able to
compute the combination effects and provided the participants with both: experimental mono-therapy
measurements and inferred synergy scores. The details on the introduced approach are presented in
section 2.1.3. Pharmacological Data.
1.3. Work Progress
While achieving the goal of this work three keypoints were successfully completed:
1. Profund understanding of the original approach;
2. Functional reproduction of the methodology;
3. Introduction of improvements to the baseline.
There were nine main tasks realized during the accomplishment (Figure 1.1.). Firstly, the work on the
project encompassed exploration and basic training on Machine Learning methods. This practice was
performed on original data sets from the DREAM competition and was based on the problems brought
within the subchallenge 1 and the collaborative round. Since both of them are not directly relevant to
the work, the details are here omitted. While fulfilling this task, the database was organized, which
served as a fundamental structure used in all following steps.
From November, the basics of the PERL programming language had been learnt. This was necessary
in order to accomplish the second part of the task – familiarization with Yuanfang Guan’s method.
Through  reading  of  the  documents  and  additional  resources  supporting  the  approach,  the
understanding and interpretation of concept were developed.
January was dedicated to direct reading of PERL scripts. It allowed exploration of how the idea was
practically implemented. The concept gain a physical structure that could be further transferred and
developed in other computational environments.
Next 2 months were spend on establishing of reproduction of original version, using R and Python
languages.  Finally,  the  functional  baseline  implementation  was  successfully  created  and could  be
evaluated.  From  this  point  on,  the  steps  performed  were  an  adds-on  applied  above  the  baseline
implementation.
In order to reflect what had been already achieved and what urges the improvement, on 28th of March
2017 the  work was  presented  to  a  small  audiency,  including both supervisors  of  this  work.  This
important revision allowed determination of a direction of the next steps. Crucial questions regarding
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to missing values imputation, final test and trainig sets and optimization were decided, resulting in a
defined improvement plan.
Contrary to expectations, at thas time, the true values of synergy scores in a challenge test set, still did
not become available to a public.  Due to this fact,  the test and training sets were generated from
known  data,  reproducing  as  accurately  as  possible  the  modeling  conditions  created  in  DREAM
challenge.
One of the most  laborious steps was the task 7 -  feature selection.  Different  methodologies were
experimented before establishing a workflow, for example Random Forests, Support Vector Machine,
Generalized linear and additive models by likelihood based boosting (GAMBoost). The final result,
accomplished with Lasso algorithm, provided a list of useful variables that shall be included in the
model to produce optimal outcome.
Finally,  task  8  including  the  training  of  machine  learning  models  and  cross  validations,  allowed
establishment of the best performing workflow, for which the results are presented in this report.
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Timeline
2016 2017
Tasks Sept. Oct. Nov. Dec. Jan. Feb. Mar. Apr. May June July Aug. Sept.
1. Familiarization with Machine Learnin methodologies
2. Familiarization with PERL and Yuanfang Guan’s approach
3. Decoding of original scripts
4. Establishment of baseline implementation
5. Definition of improvement plan
6. Re-establishment of training & test set
7. Feature selection
8. Cross validation, model optimization & evaluation
9. Report writing
Figure 1.1. Plan of work and tasks realized in the project. 
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2. The AstraZeneca-Sanger Drug Combination Prediction
DREAM Challenge
As stated before the goal of this challenge is to expand the understanding of drug synergy and to
identify  biomarkers  driving  a  patient’s  response.  Although  the  competition  encompasses  two
subchallenges, the focus of interest was only one of them - closer to the reality, so more interesting and
important from this point of view. It reproduces the common situation in personalized medicine where
the therapies must be determined and selected only on prior knowledge. Thus, the aim is to predict in
vitro drug synergy without the access to the combinational therapy training data. The effect needs to
be inferred from multi-sourced molecular data, compound information, experimental results of mono-
therapies and/or any relevant prior knowledge and external datasets (Figure 2.1.).
Figure 2.1. Visualization of the concept of subchallenge 2 [19].
Along this work, the gene names and symbols are normalized according to standard defined by the
HUGO  Gene  Nomenclature  Committee  at  the  European  Bioinformatics  Institute.  The  cell
nomenclature is standard and common between worldwide laboratories, uniquely identifying the lines
and their origin.
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2.1. DREAM Challenge Data
2.1.1. Pharmacological Data
In  order  to  generate  the  pharmacological  data,  the  experiments  on  85  different  cancer  cell  lines
belonging to 6 different tissue types (Figure 2.2) were performed.  The trials were realized on 910
unique drug-pairs combining 118 unique drugs. If  all  potential  combinations would be considered
number of possible observations reaches 586,755, while only ~11.5k (~ 2%) cases were covered in the
experimental design. Thus the data space that could be represented in a form of a matrix with axes
corresponding to drug 1, drug 2 and the cell line, would be highly sparse turning the modeling even
more complex.
Figure 2.2. Tissue-of-origin of the samples in the study.
The study was constructed on the fundamental concept that any anticancer drug or combination of
drugs affects the tumour cells causing their death. This effect is correlated with the dosage of the
pharmaceutical applied and can be expressed by the change in the cell viability. Since the very detailed
information on assay is needless in the context of this work, only general view on the assay design will
be  provided,  briefly  presenting  the  approach  used  to  estimate  such  a  dose-response  curve
characterizing the particular cell-treatment process. 
On the purpose of the experimental study, the samples were collected giving origin to the cell line
cultures that were prepared and afterwards distributed among the plates. Each single tested drug (in
case of mono-therapy) or drug-pair (in case of combination therapy) was dosed among the wells with
particular cell line in 5 different concentrations per compound. After 5 days of incubation and staining
step, the fluorescent intensity was read allowing determination of the numbers of dead cells per each
well. Next, the total cell numbers was obtained in re-read of plates and the calculation of the living
units was performed. The observed change in living cells (expressed in percentages) was determined
due to normalization of computed values to control samples where no treatment was applied.
Mono-therapy
In the mono-therapy assays the single drug is applied to the samples and the response of cancer cells is
recorded.  Majority  of  the  biological  processes  follow  the  sigmoidal  form  and  they  are  usually
summarized  by  4-parameter  nonlinear  logistic  equation,  the  Hill  equation  [20][21]. The  dosage-
response curve is fitted to 5 experimental points and in most of the cases approximates to a sigmoidal
shape (Figure 2.3.).
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 Figure  2.3. Dosage-response  curve  fitting  (Hill  equation)  for  exemplar  mono-therapy  experiment  for
CHECK1 drug [22].
As could be expected, the plot reflects a common relation between treatment dosages and cell viability.
The low concentrations of drug have null or nearly null effect, leaving 100% of cells alive. Contrary,
while applied dose is high, it is able to cause total death of cell culture (0% of survivability). The
experimental plots are created by drawing the observed effect  Eα  against drug concentration  α, and
they serve for fitting the dosage-respond equation (2.1.). 
Eα=100+
E∞−100
1+(
IC50
α )
H (2.1 .)
The  determination  of  coefficients  allows  characterization  of  the  drug  activity  in  a  particular  cell
through  the  following  parameters:  maximum  change  in  cell  viability- E∞,  dose  causing  50%  of
maximum cell death- IC50 and slope of the plot- H.
Combination therapy
Greco et al, 1996 [23] 
In the combinatory treatment the effect on a cancer cell survival is observed after application of a two
pharmaceuticals  simultaneously.  In  this  case  the  experimental  results  can  be  presented  in  3-
dimensional space where the observed difference in a cell count are plot against the plane of two drug
concentrations (Figure 2.4.) creating dosage-response surface. 
Figure 2.4. Dosage-response surface fitting. Example of combinatory therapy outcome for drug pair ATR4 and
CHEK1, carried out on human bladder carcin.oma RT112 cell line [22].
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“The search for synergy (...) is reminiscent of Dorothy ["The Wizard of Oz"] and the ruby slippers.
(...) it is often assumed that proper and easy synergy assessment is possible
but that it is necessary for some wizard to tell us the secret.”
The dosage-response surface reflecting observed effect (E) consists of two sublayers that correspond
to additive (A) and synergistic (S) effects (Figure 2.5.). First of components is understand as a basic
response when the combination stays neutral and does not affect the cancer cells in any manner. The
extra effect S is the one that actually causes the change in cell viability. Thus, it is the aim of interest
since it  captures  the  synergistic  (if  positive)  or  antagonistic  (when negative)  character  of  relation
between the two drugs, when acting on a particular cell line.
Figure 2.5. Graphical representation of principle for computation of the extra-effect (S) distribution [22]. 
In order to estimate the extra effect, the additive effect is determined on mono-therapy data [17] and
afterwards subtracted from the observed one.  This is accomplished applying the Loewe model  [24]
[25],  which  relies  on  the  isobole  equation.  Firstly,  the  baseline  effect  A is  calculated  by  solving
numerically the referred equation for all dose concentrations and next the synergistic effect layer S is
derived. In order to express the extra effect by a single value, the distribution of S is integrated
in  function  of  logarithmic  drug concentrations  space,  and the  total  synergy score  (SS)  is
delivered.
Data Structure
The Combenefit1  is an open-source platform providing advanced visualisation tools and model-based
quantification and analysis methods for drug combination trials  [26]. It was utilized to organize and
manipulate the raw experimental outcomes, to fit the Hill  equation to data points,  to compute the
coefficients and calculate the total synergy scores. 
For the use of the software, the experimental results are stored in separate standard .xls and .csv files
for each drug pair – cell line combination, created according to the specifications. The template is
equal for mono- and combinatory therapies (Figure 2.6.). The top part records the cell counts obtained
for all dose concentrations for both compounds. In the bottom, specification of run experiment can be
found-  identification  of  drug  combination,  the  name  of  cell  line  and  units  used  to  express  the
concentration.
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1 http://sourceforge.net/projects/combenefit/; Last accessed on 17/09/2017
 Figure 2.6. Structure of the .xls and .csv files storing information on combination and mono-therapy assays.
* ‘Data’  - Numeric; Percentage of survivor tumour cells observed for each treatment.
* ‘Data’  - as above; available only for combination therapy assays.
Some of the trials had to be repeated due to unsatisfactory level of quality of the measurements and all
the experiments are recorded in separate files.  The duplicates and triplicates are identified by the
adequate suffix in the file name, respectively: *.Rep2 and *.Rep3. In total there are 11,759 available
files  corresponding  to  the  mono-therapy  assays  and  6,731  storing  the  results  of  combinatory
experiments. 
After Combenefit manipulations, plotting and Hill’s equation fitting, the results are summarized and
stored in a .csv file with 14 fields (Appendix 1A). Among the recorded information, there can be found
combinatory effect coefficients, quality assessment, specification of a drug pair – cell line combination
and finally the total synergy score value.
2.1.2. Molecular Data
Three molecular data sources: gene expression, copy number variants and mutations in cancer cell
lines, were produced in a frame of one of the Sanger Institute projects, namely the Genomics of Drug
Sensitivity  in  Cancer  (GDSC).  The  methylation  data  was  generated  by  the  Estseller  group  from
Bellvitge  Biomedical  Research  Institute  (IDIBELL).  All  this  molecular  data  provided  within  the
DREAM challenge is available at COSMIC repository (COSMIC2012) in a format of .csv files. The
gene names and symbols used in the work are normalized according to standard defined by the HUGO
Gene Nomenclature Committee at the European Bioinformatics Institute. To allow easy transfer and
sharing of information, the cell nomenclature is standard and common among worldwide laboratories,
uniquely identifying the lines and their origin.
Gene Expression
Regarding to the data on RNA expression, it comes from a study performed using Affymetrix Human
Genome U219 Array Plates,  available  at  ArrayExpress  platform:  E-MTAB-3610 [27].  The values
provided was obtained  after  processing  the  raw data  in  R utilizing tools  implemented  within the
Bioconductor  [28].  Firstly,  the  package  ‘makecdfenv’  [29] was  applied  to  read  Affymetrix  chip
description  file  (CDF)  and  allow  mapping  between  probes  and  genes.  Next,  the  values  were
normalized with Robust Multi-array Average (RMA) algorithm employing R-package ‘affy’ [30]. The
2-dimensional matrix holding processed values of a gene expression has 83 rows listing the cell lines
and 17,419 columns corresponding to the genes. It also contains missing values due to the unavailable
data for two cell lines: MDA-MB-175-VII and NCI-H1437.
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Dose 1 Data Data Data Data Data Data
Dose 2 Data Data Data Data Data Data
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Dose 4 Data Data Data Data Data Data
Dose 5 Data Data Data Data Data Data
(=Agent 1)
Agent 1 Drug A name
Agent 2 Drug B name
Unit1 Concentrat ion (\muM)
Unit2 Concentrat ion (\muM)
Title Cell line name
Copy Number Variations
Another  data  set  provides  the  knowledge  on  Copy  Number  Variations  (CNVs).  It  was  generated
employing Affymetrix SNP6.0 microarrays and can be found at European Genome-phenome Archive:
EGAS00001000978 [27]. The chromosomal alterations were identified using the  PICNIC algorithm
[31] with the reference to 38 human genome build (GRCh38). The data provided reveals the state of
chromosome at two levels: of the segment and gene. Since the approach presented in this work focuses
on genes  and simulates the  posterior state on the gene level,  exclusively the last  source of  CNV
information was considered in the preparation of the model. The respective .csv file is a list of CNVs
that encompasses 29,158 observations for each of 85 cell lines (that is 2 478,430 unique records in
total) and contains 9 fields (Appendix 1B) revealing specifications of each gene alteration.
Mutations
In order to obtain detailed mutational profile for the cancer cell lines, the whole exome sequencing
was performed with the Agilent’s SureSelect on the Ilumina HiSeq 2000 platform. Raw BAM files are
available on repository with mentioned above CNV data (EGAS00001000978 [27]). Two algorithms
were  applied  to  identify  mutations,  namely  the  CaVEMan (Cancer  Variants  Through Expectation
Maximization) and PINDEL [32], allowing calling of the total 75,281 mutations for all 85 cell lines.
The resulted output data was organized in a single .csv file with 32 fields (Aappendix 1C) including all
the specifications and details of detected mutation.
Methylation
One of a studies held at IDIBELL Institute and carried by the Esteller team provided the molecular
data on methylation.  The project  was performed at  Illumina Infinium HumanMethylation450 v1.2
BeadChip platform and the raw data is stored at a public Gene Expression Omnibus (GEO) repository:
GSE68379 [27]. The methylation status can be expressed by two different parameters  [33]: 
- the  betai methylation status of  yi CpG site, which is a ratio of maximal methylated probe
intensity versus the total sum of maximum methylated and unmethylated intensities (Eq. 2.2.);
beta i=
max ( y i ,methylated ,0)
max ( yi ,methylated ,0)+max ( yi , unmethylated ,0)+α
(2.2 .)
- value Mi,  expressed as logarithm of ratio of maximum methylated and unmethylated probe
intensities (Eq. 2.3.).
M i= log2 (
max ( yi , methylated ,0)+α
max ( yi ,unmethylated ,0)+α
) (2.3 .)
Both metrics are computed with correction through a coefficient α that is variable specific for the
platform used in the assay, in this case – one recommended for Illumina. Available beta and M scores
are defined per probe and CpG island. Thus, there are four datasets provided with methylation status
expressed  by  beta and  M metrics,  probe-  and  island-  wisely  each.  Following  Yuanfang  Guan,
unlogged ratios assigned per probe were used as involving less transformations on raw values. The
methylation data  is  organized within the 2-dimensional  matrix with 28,7450 rows referring to  all
unique  probes  included  in  the  assay  and  82  columns  corresponding  to  the  studied  cell  lines
(unavailable data for MDA-MB-175-VII, KMS-11, SW620).
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2.1.3. Compound Data
The data on chemical and structural properties for 118 unique drugs involved in the experiments is
provided in the .txt file with 8 fields (Appendix 1D). For each compound with anonymised name,
chemical and structural properties are specified including the targets of action, specification on H-
bond acceptors and donors (HBA and HBD), octanol-water partition coefficient (cLogP), number of
fulfilled Lipinski rules (Lipinski), SMILES or PubChem identificaton and molecular weight. Worth of
noting  is  a  fact  that  since  the  identity  of  all  compounds  is  anonymized  due  to  a  confidentiality
agreements, the information on drugs provided within this file is the one to rely on. The only possible
alternative to make a connection with a prior knowledge is throught the SMILE or PubChem ID,
however this field is unavailable for 33% of instances.
2.2. Submission Form
After building a model, the final predictions could be submitted on a Synapse platform. The accepted
format is a comma separated text file holding a synergy prediction matrix that contains cell lines in
columns and drug combinations in rows (Figure 2.7.). The predictions shall be expressed in binary
form, identifying synergy (=1) and non-synergy (=0). The prediction assigning ‘0’ value to a drug pair
– cell line combination, stands for the antagonism, null effect or additivity. The models are tested for
ability to determine synergistic instances.
Figure 2.7. Form of synergy prediction matrix accepted for final submission in subchallenge 2 [34].
The participants were also asked to provide the  .csv file, equally structured, containing confidence
scores of corresponding produced predictions. However, it is not relevant in the context of this work
and so its description is omitted.
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3. The Winning Solution
This work was inspired on the winning solution of the 2016 AstraZeneca-Sanger Drug Combination
Prediction DREAM Challenge. The implementation is provided by exceptional researcher Yuanfang
Guan from a Department of Computational Medicine and Bioinformatics at University of Michigan.
Over  last  4  years  she  with  her  team  participated  in  7  individual  DREAM  competitions,  some
consisting of 2 or 3 subchallenges, always being recognized among the top performing teams. Fifteen
submissions of GuanLab became 1st place winning solutions  (Table 3.1.),  including challenges on
various diseases (ex.  cancers,  Alzheimer,  Rheumatoid Arthritis)  and broad range of tasks to solve
(classification, prediction, inferrence problems). This achievements prove the excelence and efficiency
of the built models. There is no doubt that general approach of problem solving developed by Guan
deserves an attention and is a valuable lesson to learn. 
Although each of submmissions is provided with script files and supporting documentation, usually
the  given  explanations  are  not  sufficient  to  easily  understand  and  accurately  reproduce  the
methodology. Exploration of Guan’s implementation requires careful examination and backtracking of
scripts, with simultaneous connecting it to the interpretation. Task become even more complicated due
to:
- absence of dockstrings and comments in scripts;
- unclean script writting, with remains of experimented commands;
- redundant programming - unnecessary manipulations, ghost-variables;
- presence of unutilized scripts – files are submitted but never called and run by wrapping
script;
- unclear origin of some input files;
- unknown pre-processing of original files.
Untill now some manipulations remain ambiguous but it was pretended to follow the indication of the
proper author cited in the opening of this chapter. The effort was made to create a reconstruction of
procedure as close to the original as possible.
The workflow of the baseline implementation include four main steps:
“Always try the easiest solution.
And the common sense – first.” 
Y. Guan
1) Building of feature vectors;
2) Generation of models;
3) Merging of predictions;
4) Identification of synergy. 
Yuanfang Guan extended a model by including additional information as presented in the following
section 3.1. Outsourced Data.
Table 3.1. GuanLab's 1st place submissions to DREAM Challenge [35].
Year Challenge Problem/Data
2017 ENCODE-DREAM in vivo Transcription Factor Binding Site Prediction Challenge
Predicting Transcription Factor Binding 
Sites
2016
ICGC-TCGA-DREAM Somatic Mutation 
Calling Challenge -- Tumor Heterogeneity and 
Evolution
Inferring tumor heterogeneity and subclone
reconstruction
2016 AstraZeneca-Sanger Drug Combination Prediction DREAM Challenge
1a. Predict drug synergy using drug 
combinational training data, expression, 
CNV, mutation, drug chemical space
2016 AstraZeneca-Sanger Drug Combination Prediction DREAM Challenge
1b. Predict drug synergy using CNV, 
mutation and drug chemical space
2016 AstraZeneca-Sanger Drug Combination Prediction DREAM Challenge
2. Predict drug synergy without drug 
combinational training data (unseen drug 
pairs)
2015 ALS Stratification Prize4Life Challenge 1. Predict survival in ALS PROACT data
2015 ALS Stratification Prize4Life Challenge 3. Predict survival for national registry data
2015 Olfaction Challenge 1. Predict olfaction response for individuals using chemical structure data
2015 Prostate Cancer Challenge 2. Predict which patients cannot tolerate chemotherapy
2014 Rheumatoid Arthritis Challenge 1. Predict patient response to different drugs
2014 Rheumatoid Arthritis Challenge 2. Predict non-responders
2014 Alzheimer BigData Challenge #1 1. Predict the prognosis of AD patients
2014 Alzheimer BigData Challenge #1 3. Classify individuals into diagnostic groups using MR imaging
2014 Broad Institute Gene Essentiality Challenge
2. Identify the most predictive biomarkers 
to predict cancer cell survivability under 
small molecule perturbations
2013 Breast Cancer Network Inference 2. Drug response of phosphorylation network prediction in cancer cells
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3.1. Outsourced Data
Beside  the  DREAM  challenge  data,  Guan’s  implementation  introduced   the   additional  prior
knowledge including molecular and functional network information. The data on RNA expression and
Copy Number Variants was outsourced from The Cancer Cell Line Encyclopedia (CCLE2012)2. This
project is a successful result of a partnership between the Broad Institute, and the Novartis Institutes
for  Biomedical  Research  and  its  Genomics  Institute  of  the  Novartis  Research  Foundation  [36].
Althought  the  data  is  available  for  more  than  1,000  of  cancer  cells,  requiring  the  filtering  of
information for relative DREAM samples, for both sources there are missing measurements for M14,
MFM-223 and NCI-H3122 lines.
Regarding the functional network data source, Yuanfang Guan included a prediction FNTM server for
tissue-specific protein interactions for the laboratory mouse  Mus musculus which the most widely
used model organism for human disease [37].
3.1.1. CCLE Expression
The outsourced gene expression data  comes  from a study performed using  Affymetrix GeneChip
Human Genome U133 Plus 2.0 platform. The raw values provided with .CEL files were merged and
summarized  for  each  probe  set  with  Robust  Multi-array  Average  (RMA) algorithm.  The  quantile
normalization was applied in order to remove the array-specific effects and guarantee the identical
statical properties of different measurement distributions among the trials. The annotation of genes
was accomplished according to the custom .CDF file released on 18th of January 2012 (ENTREZG,
version  15).  The  dataset  is  a  2-dimensional  matrix  with  18,988  probes  with  assigned  genes  (if
applicable) and total of 1,037 human tumour cell lines.
3.1.2. CCLE CNVs
Another prior knowledge was provided within the study carried on Affymetrix Genome-Wide Human
SNP Array 6.0., bringing the additional molecular information on CNVs.  After merging the  .CEL
files, linear calibration curves were estimated for each probe set, allowing identification of the copy
numbers.The measurements were normalized utilizing the most similar HapMap control sample as
reference. The circular binary segmentation (CBS) algorithm was applied in order to call segments on
log2 ratios. Obtained dataset has a structure of 2-dimensional matrix with the copy number values for
23,316 genes and 1,043 cell lines.
3.1.3. Functional Networks of Tissues in Mouse
The  functional  network  predicts  the  probability  that  a  pair  of  proteins  is  involved  in  the  same
biological process. One of the most comprehensive platforms holding this data - Functional Networks
of Tissues  in Mouse (FNTM)  [37],  was created by Laboratory for  Bioinformatics  and Functional
Genomics in the Lewis-Sigler Institute for Integrative Genomics at Princeton University, and is free
available3.  It  was  a  database  of  preference  since  Yuanfang Guan is  probably  highly  familiar  and
closely connected with the work, considering a fact that her PhD in Molecular Biology, as well as
Postdoctoral Fellow in Integrative Genomics were both accomplished at Princeton University.
15
2 https://portals.broadinstitute.org/ccle; Last accessed on 21/09/2017
3 http://fntm.princeton.edu/; Last accessed on 22/09/2017
In  order  to  generate  the  network  in  mouse,  diverse  data  sources  needed  to  be  integrated:  gene
expression,  tissue  localization,  phylogenetic  and  phenotypic  profiles,  data  based  on  homology,
physical interactions and gene-disease/phenotypic associations. According to the Yuanfang Guan [38]
creating such a functional network in mammalian models is still challenging. Thus using the much
simpler mouse network that could reveal major connections and relations between proteins could be
applicable in human models by inference.
In brief, according to the author, the procedure of determining the functional relations between the
genes and their connection probabilities encompasses five main steps [39]:
1) Pick all possible files with available data related to genes, for example microarrays, RNA-
seq, phenotypes, sequences, homologies etc.
2) Compute correlations between genes and normalize them using z-transform.
3) Build a gold standard set using KEGG/GO.
4) Bin each into a number of bins.
5) Compute the Bayesian posterior with some regularization.
As could be expected this process is computationally highly intensive.
3.2. Feature Vectors
The final predictions are obtained by computing a weighted average from six separate models:
- global molecular,
- global mono-therapy,
- chemical,
- file-counting,
- local molecular,
- and local mono-therapy.
Each of those involves independent construction of feature vectors, for which different data sets serve
as a sources and particular handling and manipulation steps are implicated. 
3.2.1. Global Molecular
The molecular feature vector is based on six  i data sources: gene expression, CNVs, mutations and
methylation that are described in details in the section 2.1.2., and additional outsourced CCLE data
presented in sections 3.1.1. and 3.1.2. The files selected to be used characterize a molecular profile of
cancer samples with regard to collection of genes. Each of them is transformed into unifrom two-
dimensional matrix (Figure 3.1.) where the columns refers to the cell lines and rows- to genes. They
are filled with vG1 – vGn values corresponding to an exact cell - gene instance, and expressing the assay
results provided with each original data source. Thus, in case of quantitative measurements, RNA
expression and methylation, they remain represented by respectively: logged intensities and level of
methylation (ranging from 0 to 1 that corresponds to 0% – 100% of methylation). For qualitative
properties like CNVs and mutations, those must be binarized assigning value '1' when the alteration is
present and '0' contrary. All those matrices serve as input for the baseline script.
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Worth noting is  a  fact  that  the  exact  files,  as  well  as  a  procedure of  file  preparation and matrix
construction is not revealed by the author, this knowledge was inferred from posterior manipulation
steps written in PERL. However still remains unclear what approach was applied regard to missing
values.
Figure  3.1. Visualization  of  the  pre-processing  step  applied  to  six  molecular  data  sources  according  to
baseline implementation.
The construction of Global Molecular Feature Vector, FVGlobalMolecular, encompasses three main steps:
1. Building of prior feature vectors, fvi, corresponding to individual data sources;
2. Simulation of molecular data under the drug;
3. Composition of posterior FVGlobalMolecular.
Prior feature vectors
Each of six uniform matrices serves for construction of a proper dictionary holding the set of partial
feature  vectors  fvi,  as  values  assigned to  unique  [CL]  cell  line  keys  (Eq.  3.1.).  The  sequence  of
variables in each of vectors follows determined order of genes  G1 –  Gn. Yuanfang Guan limited the
features included in construction of vectors exclusively to a set of target genes (Figure 3.2.).
fv i[CL ]=[vG1, vG 2, vG3, ... , vGn] (3.1)
17
Figure  3.2. Visualization  of  construction  of  partial  feature  vectors  fvi,  from  uniform  matrices  holding
molecular data, with a step of filtering target genes.
All molecular sets  have their  particular  target  gene lists.  Those were apparently created from the
challenge data file on chemical and structural properties of drugs (2.1.3. Compound Data), with regard
to genetic property. Again, the process of preparation is unrecorded, however the specific gene lists
used in the implementation were generously provided by the author after the final submission.
As a result, six dictionaries are created holding prior feature vectors:  fvexp,  fvcnv,  fvmut,  fvmeth,  fvCCLEexp,
fvCCLEcnv,  corresponding to cancer cell  lines, and based on respective data source: RNA expression,
CNVs, mutations, methylation, CCLE expression and CCLE CNVs. 
Simulation of molecular data under the drug
Importantly, this is a key step. Molecular data provided in the challenge (see details in section 2.1.2.
Molecular Data) is basically useless if not simulated to  posterior values under the applied drugs. In
order to obtain the molecular profiles after the treatment for each cell line – drug pair case, the prior
knowledge from FNTM (see 3.1.3. Functional Networks of Tissues in Mouse) was used. The principal
idea was to alter each original state according to the probability of connection between two genes: the
target gene for the particular drug and the gene in consideration. The simulation was performed basing
on the source .txt file provided by the Yuanfang Guan beside the submitted solution. The file contains
information on the architecture of the functional network in the mouse. Thus, each line corresponding
to a single connection indicates two genes and the value of linkage probability (Figure 3.3.), including
in total the network of 211778490 relations. 
Figure 3.3. Inspection of the head of source file containing information on probability of connections in
functional network in mouse.
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As  could  be  expected,  the  names  of  genes  are  expressed  according  to  the  official  nomenclature
established  by  the  International  Comitee  on  Standardized  Genetic  Nomenclature  for  Mice  that  is
available in the Mouse Genome Informatics Database4. In order to take advantage of this information,
the MGI identificators require to be converted to HGNC nomenclature used as a standard.  The file
called by PERL script in order to accomplish the translation was not originally provided. It was found
throught the search in the internet and downloaded from the GitHub repository5, thank to the nkiip user
that generously shared a file on the 15th of May 2016 and made it available.
The concept  of  simulation follows the common sense and reflect  the simplified reality.  The basic
assumptions are:
1) The efficiency of treatments is ideal and once applied they totally turn off the genes that are
the drug targets.
2) The genes that are not targets for applied drug, neither connected to target genes: their state
remains unchanged (the treatment has no effect on them).
3) Treatment alterates the state of genes related to the drug targets according to the connection
probability between those genes. 
For  the  special  attention  deserves  last  of  the  rules.  It  cannot  be  applied  automatically  since  the
‘direction’ of  alteration  must  be  considered,  i.e.  if  the  molecular  state  promotes  or  limits  the
carcinogenesis. The action of a drug is always directional: contra the tumour, what means that it shall
promote anticancer events and reduce those which are pro. Following the general rules stated above,
particular cases can be considered. 
Concerning expression, the gene state for each cell line is described by the log2 of measured intensity
so the matrix is filled with continuous values. The expression of the gene that is a drug target for the
applied drug turns zero- reflecting the total silencing. Genes that are functionally linked to the target
reduce their intensities according to the connection probability (Eq. 3.2.). This simulation approach is
valid for both expression data sources – one provided within the challenge and other outsourced from
the CCLE platform.
vGn[exp , posterior ]=vGn[exp , prior ]∗(1− pconnection) (3.2 .)
The information in a CNV matrix is binarized, expressing the gene states by discrete data. According
to the main concept, target genes turn zero because their activity is totally recovered under a treatment,
and the copy number does not promote the growth of cancer any more. The activity of connected
genes becomes partially normalized, their status reduces proportionally to the linkage with a target,
and in consequence has less impact on tumorigenesis (Eq. 3.3.). The simulation of a CNVs posterior
status for a dataset outsourced from CCLE shares the same logic.
vGn[cnv , posterior ]=vGn[cnv , prior ]∗(1−pconnection) (3.3 .)
For mutations that are also organized in binary matrix, the assumption of ideal treatment would be
high to far unrealistic. This is an exception since the drugs applied nowadays are yet unable to fix the
pro-cancer mutations in any manner. Thus, the state of target genes remains unchanged while values
assigned to related genes are multiplied by the connection probability (Eq. 3.4.). Note, that in this case
the manipulation will always bring reduction of a molecular state: gene carrying mutation is assigned
with ‘1’ and if is connected to target, will turn < 1, according to a probability that is always below 1. It
can be interpreted as although the target mutation cannot be fixed, the treatment will have still an
indirect impact, improving other related processes.
vGn[mut , posterior ]=vGn[mut , prior ]∗(1− pconnection) (3.4 .)
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4 http://www.informatics.jax.org/mgihome/nomen/; Last accessed on 22/09/2017;
5 https://github.com/nkiip/GC2NMF/blob/master/0_origin_data/MGI_Gene.rpt; Last accessed on 25/09/2017;
In the case of methylation, matrix is filled with continues values that range between 0 and 1 and that
correspond  to  a  percentage  of  methylation  level.  The  simulation  according  to  Yuanfang  Guan  is
practically proceeded as follows: the target genes become totally unmethylated while the related genes
proportionally  decrease  their  methylation  level.  However  the  script  does  not  correspond  to  the
documentation  [39]. The author states that for both- target genes and those connected, status turns
bigger (proportionally to the connection probability in latter case, as usually). 
Due  to  this  discrepancy,  the  additional  research  was  performed  to  understand  the  methylation
processes underlying the carcinoma and decide on approach to implement. In cancer cell lines  two
phenomena are observed [40][41]:
- hypermethylation of CpG sites that causes the inactivation of tumor-suppressor genes,
-  genome  widespread  hypomethylation  that  promotes  the  carcinogenesis  and  the  tumor
progression.
Remembering that the data provided in challenge contains the measurements captured in CpG sites, it
seems reasonable and convincing to define the process of simulation under the drug as followes: the
target  genes  become  totally  unmethylated  turning  their  status  to  zero  (allowing  tumor-suppressor
genes to fight against the cancer), while related genes reduce the methylation level according to the
connection probability (Eq. 3.5.).  This approach, equal to included in PERL script,  was proved to
result in more accurate model and so was decided to be implemented in this work. 
vGn[met , posterior ]=vGn[met , prior ]∗(1− pconnection) (3.5 .)
Interestingly,  Yuanfang  Guan  claims  that  the  inclusion  of methylation  data  apparently  hurts  the
performance  [39].  This fact  confirms the theory that  proposed methodology of  methyl  simulation
could be imperfect and an alternative manner shall be applied.
Summarizing, each of prior feature vectors is processed and all  vG1 – vGn  values are substituted with a
new state, generating simulated feture vectors, fv’i.
Posterior feature vectors
In  order  to  generate  the  global  molecular  feature  vectors  FVGlobalMolecular,  reflecting  the  molecular
profiles of samples, the simulated partial feature vectors are joined (Eq. 3.6.) according to their  cell
line annotation.
FV GlobalMolecular [CL ]=[ fv ' exp , fv ' cnv , fv 'mut , fv 'met , fv ' CCLEexp , fv ' CCLEcnv ] (3.6 .)
3.2.2. Global Mono-therapy
The idea of mono-therapy modeling is to produce the predictions basing on pharmacological sources
with the experimental and curve-fitted variables. The feature vector is constructed from the original
cell  counts  observed in  assays and estimated Hill  model  parameters.  Due  to  a  complexity of  the
procedure  it  is  convenient  to  define  some common terminology for  the  purpose of  this  work,  to
provide clearer and simpler description of the data manipulation.
Along this  lines,  denomination  ‘yA1-5’ is  used  for  cell  counts  obtained  under  the  drug  A for  five
different dosages. Similarly, ‘yB1-5’ stands for changes in cell viability observed for five concentrations
of drug B. Recalling the coefficients estimated by curve-fitting, the following designation of variables
is applied:
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MAX_CONC_A→zA1 
MAX_CONC_B→zB1
IC_50_A→zA2
IC_50_B→zA2
H_A→zA3
H_B→zA3
Einf_A→zA4
Einf_B→zA4
The construction of global mono-therapy feature vector  FVGlobalMonotherapy, encompasses six basic steps
that are repeated for three different ways of ordering variables identified as: ‘max_min’, ‘B_A’ and
‘A_B’. Thus, in total there are 18 partial feature vectors (6 x 3 orders) that are created by the same
number of separate PERL scripts and saved in individual  .txt files.  Unlike in the case of a global
molecular feature vector, which was generated for each cancer sample, here it is required to build a
vector for each drug pair - cell line combination [drugA.drugB.CL]. Equations pesented below (3.7. -
3.18.) express the algorithms applied in order to generate the partial feature vectors fvi, where index
‘exp’ indicates a vector based on experimental data, i.e. the cell counts, and ‘eqHill’ - on parameters
computed in dosage-response curve fitting.
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fvexp,max_min [drugA . drugB .CL ]  = 
(max ( yA1 ,y B1 ) , min ( y A1 ,y B1 ) , ( y A1 +yB1 ) , . . . , max ( y Ai ,yBi ) , min ( y Ai ,yBi ) , ( y Ai +y Bi ) )
(3.7 .)
(3.8 .)
fv'' exp,max_min [drugA .drugB .CL ] = fvexp, max_min [drugA . drugB .CL ]−avg ( yCL . i ) (3.9 .)
fv eqHill, max_min [ drugA .drugB .CL ]  = 
(max ( zA1-2 , z B1-2 ) , min ( zA1-2 , z B1-2 ) ,  log (zA1-2 + z B1-2 ) , . . . , max ( zA3-4 , z B3-4 ) , min ( zA3-4 , z B3-4 ) , ( z A3-4+ z B3-4 ) )
(3.10 .)
fv' eqHill, max_min [drugA . drugB . CL ]  = fv eqHill, max_min [ drugA . drugB . CL ]−
(avg ( z drugA.CL . i )  + avg ( zdrugB .CL . i ) )
2
(3.11 .)
fv'' eqHill, max_min [drugA . drugB .CL ]  = fv eqHill, max_min [drugA . drugB . CL ]−avg (zCL . i ) (3.12 .)
fv'' exp [ drugA . drugB . CL ]  = fv exp [ drugA . drugB .CL ]− avg ( yCL . i )
fv exp [drugA . drugB . CL ]  = ( y B1-5 , yA1-5 )
(3.15 .)
(3.14 .)
fv' exp, max_min [drugA . drugB . CL ]  = 
fv exp, max_min [drugA .drugB .CL ]−
( avg ( y drugA .CL. i) + avg ( ydrugB .CL .i ) )
2
(3.13 .)
fv eqHill, B_A [ drugA .drugB .CL ]  = 
( zA 1 , z B1 , log ( zA1 + z B1 ) , z A2 , zB2 , log ( zA2 + z B2 ) , z A3 , zB3 , ( zA3+ z B3 ) , zA4 , zB4 , ( zA4 + zB4 ))
fv' exp,B_A [drugA . drugB .CL ]  = 
( fv exp, B_A [ drugA .drugB .CL ]1-5− avg ( ydrugB .CL . i ) ,fvexp, B_A [drugA .drugB .CL ]6-10− avg ( y drugA.CL . i ) )
(3.16 .)
The process of generation of resting six partial feature vectors fvi, corresponding to ‘A_B’ ordering is
analogous to approach expressed by equations 3.13. – 3.18., just with a reversed sequence of variables.
Finally, the global mono-therapy feature vectors are generated by merging of all the produced partial
vectors  (Eq.  3.19.)  regarding  to  a  specific  drug  pair  -  cell  line  combination  [drugA.drugB.CL]
correspondence. Thus each of them includes 189 predictor variables.
FV GlobalMonotherapy [drugA . drugB . CL ]  = 
[ fvexp, max_min , fv' exp, max_min , fv'' exp, max_min , fv eqHill, max_min , fv' eqHill, max_min , fv'' eqHill, max_min , ...]
3.2.3. Chemical
One of the simplest and quickest to generate is the chemical feature vector, FVChemical. The file holding
information on specific properties of drugs (see 2.1.3.  Compound Data) contains large amount of
missing data: among 119 observations only 58 contain complete information. It is totally unclear how
Yuanfang Guan decided to deal with this issue since the direct input file entering the PERL script is
not provided, neither described by the author. 
For each drug pair - cell line combination [drugA.drugB.CL], two chemical feature vectors are created.
The difference between them is again in the order of variables. Thus one of the vectors consider the
‘A_B’ order while another – reverse. They encompass five variables, characterizing each of drugs from
applied pair (resulting in 10 in total), namely: number of H-bond acceptors and donors (HBA and
HBD), calculated octanol-water partition coefficient (cLogP), the number of fulfilled Lipinski rules
(Lipinski) and molecular weight (MW) (Eq. 3.20. and Eq. 3.21.).
FV Chemical [ drugA.drugB .CL ]  = 
[HBAA , cLogP' A , HBDA ,Lipinski A , MW A , HBAB , cLogPB , HBDB , LipinskiB , MW B]
FV' Chemical [drugA.drugB .CL ]  = 
[HBAB , cLogP' B , HBDB , LipinskiB , MW B , HBAA , cLogP A , HBDA , LipinskiA , MW A]
Since the prediction for each combination is doubled and based on original and reversed order of
drugs, the model become immune for the fact which of compounds in a pair is indicated as a first, and
which as a second.
3.2.4. File-counting
Putting  it  simple,  the  idea  of  file-counting  branch is  to  build  a  model  basing  on  the  amount  of
information  available.  That  is  important  since  the  experiments  were  not  equally  performed  -  the
number of assays carried on cancer samples differ among the cell lines (for some there are more data
available than for others). Also the drugs were not uniformly included in run tests and in the effect the
knowledge on their action is not identical. In order to generate a fair final model this imbalance is
taken into consideration.
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fv' eqHill, B_A [ drugA .drugB .CL ]  = 
( fv eqHill, B_A [drugA . drugB .CL ]1,3,4,5− avg ( z drugA .CL . i) ,  fveqHill, B_A [ drugA . drugB .CL ]2,6,7,8− avg ( zdrugB .CL . i ) )
fv'' eqHill, B_A [drugA . drugB . CL ]  = fv eqHill, B_A [ drugA . drugB .CL ]− avg (zCL . i )
(3.17 .)
(3.18 .)
(3.19 .)
(3.20 .)
(3.21 .)
No  pre-processing  is  required  in  file-counting  branch  and  the  feature  vector  can  be  created
straightforwardly. The PERL script run through all the experimental files that are available saving and
analysing  their  names.  Since  the  denomination  of  files  follows  common  pattern:
drugA.drugB.CL.Rep[0-9].csv it is enough to extract the necessary information on drug pair and cell
line used in assay. Passing all the names, the total counts of interest are produced:
- number of files corresponding to a particular cell line: # files[CL],
- number of files corresponding to a particular drug: # files[drugA] and # files[drugB],
- and number of files corresponding to a particular pair of cell and drug (considering drugA
and drugB separately): # files[drugA.CL] and # files[drugB.CL].
Finally, for each drug pair - cell line combination, two file-counting feature vectors are created (Eq.
3.22. and Eq. 3.23.). They encompass five variables: three are the direct counts obtained as described
above and additional two are the ratios created on base of direct counts. 
Contrary to previously presented doubled feature vectors for chemical data, those two do not enter
together  to  the  model  building step.  Separate  predictions  are  produced basing on the information
corresponding to the drugA and to the drugB, and averaged only afterwards giving the final output.
3.2.5. Local Molecular and Mono-therapy
Those two feature vectors are created as their global versions already described (see 3.2.1. Global
Molecular and 3.2.2. Global Mono-therapy). The difference comes afterwards, only while building the
models. Due to this fact, more details on this mattter can be found in the following section.
3.3. Models
Following  the  approach  of  Yuanfang  Guan,  the  random  forest  algorithm  is  applied  to  built  the
predictive models. Original PERL scripts call the TreeBagger() function implemented in the MathLab
[42]. The separate models are created for each future vectors, growing 200 trees for each, using all
variables as the sets of predictors. The response or outcome variable is the total synergy score, drug
pair – normalized. The predictions obtained from each partial model, are saved in individual .txt files
with a standard structure, where each line contains identification of a cell line, drug pair combination
and the predicted value (Figure 3.4.).
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FV [drugA .drugB .CL]  = 
(# files [CL ] , # files [ drugA] , # files [ drugA .CL ] ,  # files [ drugA .CL ]# files [ drugA] ,  # files [ drugA .CL ]# files [ CL ] )
FV File-counting [drugA . drugB .CL ]  = 
(# files [CL ] , # files [ drugB ] , # files [ drugB .CL ] ,  # files [ drugB . CL ] # files [drugB ] ,  # files [drugB .CL ]# files [CL ] )
(3.23 .)
(3.24 .)
Figure 3.4. Inspection of the head of exemplar output file of a single branch modelling, holding information
on cell line, drug pair combination and finally value of produced prediction.
Not all feature vectors are processed in the same manner. This is espcially valid for a case of molecular
and mono-therapy data where separate predictions are produced using global and local models. 
3.3.1. Global models
What is considered as a global model is a model built on entire dataset available (Figure 3.5.). There
are all cases and observations included, no filtering, subsetting or slicing of information is performed
before.
Figure 3.5. Visualization of 3D matrix with available data. All data points enter the global model to produce
predictions.
There are three feature vectors proceeded with this approach: global molecular, global mono-therapy
and chemical. Another characteristic of global modelling here applied, is that three separate runs are
performed and the predictions are averaged to give the final outcome. In the case of molecular and
chemical data, the training and test inputs are equal for the models, unlike for the mono-therapy step.
Since  the  feature  vectors  are  created  with  different  orders  of  variables,  those  serve  for  creating
individual  training  and  test  sets  (Figure  3.6.).  One  of  models  is  trained  and  tested  on  data  sets
constructed from feature vectors with the basic ‘A_B’ ordering. Another two share a common training
set that encompasses feature vectors with both orderings: ‘max_min’ and ‘B_A’. Afterwards, they are
tested on disjoint datasets created respectively from ‘B_A’ and ‘max_min’ vectors. 
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Figure 3.6. Visual representation of global modelling procedure performed for mono-therapy branch.
The individual models are joined by averaging four predictions, taking into account a duplicate of the
last model outcome (3.25.).
3.3.2. Local models
On  the  other  hand,  the  concept  of  local  models  is  to  use  for  modeling  just  some  part  of  the
information. In practice it means, that in process of iteration among all drug pair – cell line  instances,
the separate small models are built and result in production of independent predictions. In the original
implementation the local modeling approach is used for three feature vectors: file-counting and for
two reproductions of global cases - molecular and mono-therapy. 
Considering a single case of [drugA.drugB.CL] combination, firstly the chemical A serves as a ‘slicing
point’ and the training set is created by selecting all the occurances related to this drug (Figure 3.7.).
Model is trained and tested delivering set of predictions. In next step, the compound B becomes a filter
and the training is performed on a dataset including only instances associated with this second drug.
Modeling is repeated, resulting in new predictions. Finally the both outcomes are merged by averaging
corresponding values.
The  processing  of  local  mono-therapy  feature  vector  is  a  special  case  and  requires  additional
comment. Although the data is sliced selecting planes of data corresponding to each of the drugs in the
pair, the subsets are joined into a single one, and after proceeded similarly to a global version - for
each feature vector order, the three separate models are prepared and merged (Eq. 3.25.).
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(3.25 .)PFVi  = ( PModel 1+PModel 2+PModel 3+PModel 3 )/4
Figure  3.7. Visualization  of  data  subsets  created  for  each  of  the  drugs  from  the  considered  pair  in
[drugA.drugB.CL] combination, that serve for building of local model.
3.4. Predictions
The response variable in the models is the total synergy score, drug pair – normalized. At first, it is not
obvious why the outcome to be predicted cannot be directly an original value provided within the
challenge data. To make it clear, the following simple example is recalled:
There are two schools, each with three classes of students. The task is to identify among both schools
the pupils that are ‘good’ in performance in one particular subject. 
But actually, when one can consider that the grade is ‘good’? When it is above some threshold? And if
the level of education at the school is very high and it becomes difficult or impossible to get this score,
shall the threshold be maintained? How to fairly compare the particular grades obtained in different
circumstances?
The solution is normalization that would eliminate the variations corresponding to variables that are
out of the scope of interest.  What does it  mean in practice? In this example, firstly the grades of
students  within  the  one  class  must  be  averaged  and this  value  need  to  be  subtracted  from each
individual score. The class-specific information becomes extracted and does not influence the outcome
any  more.  The  performance  of  students  within  the  single  school  can  be  compared.  Further,  the
procedure must be repeated but for pupils within a single institution: the school average is subtracted
from  each  individual  grade.  In  this  way  the  values  become  comparable  between  the  different
educational environments.
How to identify which students performance is ‘good’? By comparing individual scores with a total
average  for  all  students  from  both  schools.  Values  above  the  midpoint  indicate  the  individuals
performing better than the norm, while those scoring below the mean – the weaker ones.
Having this simple example in mind, let us turn back to the aim of this work and draw the analogy.
The  total  synergy  scores  SS,  computed  according  to  the  procedure  described  in  section  2.1.1.
Pharmacological Data, come from different contexts, reflecting the bahavior for different drug pair –
cell line combinations. In order to make them comparable, they require to be normalized, as grades
among different classes and schools. In the cohort of various assays, if we consider only a subset of
trials  carried on the same drug-pair  (and various cell  lines),  the  obtained scores  must  contain an
‘amount of information’ that is shared and equal for those tests.  That is a baseline specific for an
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applied treatment, that characterizes a compound-pair. Again, focusing on a subset of experiments run
on the same cell line (and various treatments), produced values have common baseline specific for a
sample  under  the  drugs.  This  concept  of  synergy  score  decomposition  (Figure  3.8.)  allows
identification of response variable that is a key value to be predicted through the established model.
According  to  the  ideia,  those  predictions  compared  with  a  total  average  value  will  permit
determination of drug pairs with synergistic or non-synergistic effect.
Figure 3.8. Visualization of an example of observed effect obtained in combinatory therapy for a drug pair -
cell line combination and scheme of synergy score decomposition.
3.5. Merging
After producing six individual prediction sets from feature vectors described in section 3.2., all the
outcomes need to be merged. The PERL script reads all the files with the partial results to separate
dictionaries. Those consist of entries where the keys are tuples formed from cell line name and drug
pair combination held in first two columns of each output record (Figure 3.4.). The value assigned to
each of the keys is a prediction itself defined in third column of a file. The merge is completed by
creating a single dictionary with all the test keys and respective final predictions, Pfinal, calculated from
the partial outcomes by weighted averageing (Eq. 3.26.).
The result obtained is saved in a  .txt file with a standard structure, identical to partial output files
(Figure 3.4.).
Finalizing, the second normalization is realized – regarding to a cell-line (see 3.4. Predictions) – to
make  the  values  comparable.  The  final  results  determining  the  predicted  treatment  effect,  are
organized in the matrix with the columns corresponding to the cancer samples, and the rows – to the
unique drug combinations. Iterating all the lines, the total sum of outcomes and the number of all
observations are calculated, allowing determination of the total average prediction value, PTotalAvg. This
value serves as a reference for identification of synergy. Thus, each instance is compared with PTotalAvg,
resulting in assignment of ‘1’ if the value is higher, and of ‘0’ otherwise. Thus, the final binary matrix
indicates respectively the cases with predicted synergy and those with the null or antagonistic effect.
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(3.26 .)PFinal  = (PGlobalMolecular+2∗PGlobalMonotherapy+PChemical+PFile-counting+PLocalMolecular+2∗P LocalMonotherapy)/4
4. Implementation & Preliminary Results
4.1. Tools
The  implementation  of  the  machine  learning  model  was  accomplished  using  basically  two
programming languages namely Python and R. This work involved also acquiring of some knowledge
and familiarity with the PERL (Practical Extraction and Report Language) since this is the language
used in original scripts written by Yuanfang Guan. In submitted solution, the predictive models were
generated  applying  the  Random Forest  algorithm by  calling   TreeBagger() function  provided  by
MATLAB. The  developed implementation  used  the  same approach however  it  was adopted to  R
environment and employed with randomForest() function.
4.1.1. Python
Python  is  one  of  the  high-level  programming  languages  successfully  combining  efficiency  and
beginner-friendliness. According to the main goals of its designer, Guido van Rossum, it was created
to be productive and readable. As broadly applicable (Web, GUI, scripting, etc.), interactive and open-
source, it gains the popularity among all communities. It is portable and extensible, and allows object-
oriented programming [43].
In this work, Python 2.7 was utilized to efficiently handle with large amount of information, especially
on data pre-processing, simulation and integration steps.
4.1.2. R
R is a free programming language and environment, one of the most popular among statisticians, data
analysts, researchers and market specialists. It provides utilities to retrieve, clean, analyze, visualize
and report data. It was designed to be intuitive and to mirror the way the user think. It is interactive,
vector-oriented and highly flexible language. R provides efficient utilities to handle  missing values,
almost impossible to avoid when working with real data [44].
In this implementation R 3.3.3 was used in data pre-processing, modeling and optimization steps. It
was found very convenient and efficient due to the diverse functions  that perfectly complemented the
capabilities of the Python.
4.1.3. Random Forests
Random  Forests  (RFs)  are  powerful  supervised  prediction  tool  for  classification  and  regression
problems. The very first method of random decision forests approach was introduced in 1995 by Tin
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Kam Ho and its increased accuracy was proved in the experiment on the recognition of handwriting
digits [45]. It was later extended by including “bagging” and random selection of features  [46][47].
RFs is an ensemble method, generating multiple fits and after all combining them to deliver improved
results. The technique uses as a principal algorithm the standard decision trees, that separate the data
into homogenous subsets, according to the most important splitter. The predicted feature is represented
by  terminal  nodes  or  leaves,  and  the  branches  are  particular  sets  of  predictors  driving  to  cohort
division.  In  brief,  the algorithm of  growing decision trees  takes  all  the root  node data  and scans
through descriptors for the best splitter (that is: for the one providing the most pure children nodes).
The one chosen divides the data and children nodes become parent nodes since the same growing step
continues starting from them. The process continues until the terminal nodes are reached and the leafs
include only homogenous subsets. However the individual trees built in greedy way are imperfect and
can easily miss the optimal solutions (the splitting decisions are made locally, instantaneously without
any general view on final outcome and without the possibility to change the past divisions).
Though the RFs idea is to take the collection of weak single tree fits, ensemble them and derive the
final outcome by averaging or voting. There is a high probability that the obtained summarized model
would  be  superior  than  any  of  the  individual,  and  that  it  would  be  resistant  to  overfitting.  The
algorithm of generating RFs includes steps as follow. (1) Specification of the N number of iterations.
(2) Bootstrap sample is picked from the original population with replacement. (3) Number of random
descriptors is selected according to the value defined by user. (4) Independent, individual tree is grown
on this subset. (5) Steps 1 – 4 are repeated N-times. (6) Collect all the trees and produce summarized
outcome. 
The RFs method was used in this work to create a baseline implementation reproducing the approach
of Yuanfang Guan. 
4.1.4. Server
This work was  performed on server with Intel(R) Xeon(R) processor of number E5-1620V4. The
processor base frequency of device was 3.50GHz while de number of cores – 8. It was equipped with
RAM of 16GiB.
4.2. Outsourced Data
An additional prior knowledge was used in order to reduce the input size and to limit the data to the
potentially most informative and relevant. It was achieved with catalog of the cancer driver genes and
map of dosage-sensitive cancer genes.
4.2.1. IntOGen Mutations
In the  development of  the cancer there can be two types  of  alterations  distinguished:  driver,  that
contribute to the oncogenesis or that are relevant to the phenotype of the cancer, and passenger which
accumulate through DNA replication but are not related to tumorigenesis. The Web platform IntOGen
Mutations, provides a comprehensive tool for identification of cancer drivers. The database is built on
the results  of  the systematic analysis of  most  currently available large data sets encompassing 28
tumor types among 6792 samples, including in the effect 1341752 somatic mutations [48][49]. There
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are 498 cancer driver genes in a database among which some are more frequntly mutated than the
others and which differ also in a scores that express the protein affecting mutations PAM (Figure 4.1.).
Figure 4.1. Cloud graph representing the most recurrently mutated cancer driver genes among total of 498.
The font size is relative to the count of samples with PAMs – Protein affecting mutations, thus mutations that
alter the function or synthesis of the protein product.
The platform uses for the driver identification Cancer Genome Interpreter6 that carries the analysis
relying  on  existing  multi-source  knowledge  and  on  computational  algorithms  which  annotate
mutations  considering  different  levels  of  evidence.  The  tool  firstly  detects  the  validated  driver
alterations and then classifies others of unknown significance using the OncodriveMUT method [50].
From IntOGen platform the .csv file with 498 cancer drivers was downloaded and served afterwards
for  filtering  of  original  data  source.  The  information  is  organized  in  a  data  frame  with  4  field
(Appendix 1E) providing repectively: HGNC symbol of gene, the specification and effect of alteration
observed, and the probability assigned for determined driver role. 
4.2.2. Copy Number Variation in Disease
The Copy Number Variation in Disease (CNVD) database7 is a reliable and comprehensive tool that
links the CNVs with multiple diseases.  It  served in this work as a base for filtering the genomic
aberrations associated with cancer [51]. The database was built through text mining methods carried
on original  CNV-related papers  published between 2006 -  2012 and downloadable  from PubMed
through EndNote software. The publications were manually analysed and the information on CNVs,
associated pathologies, genes, chromosomes and other characteristics of aberrations was recorded and
organized in Web platform. For the purpose of this work the .txt file listing tumour-related CNVs was
retrieved from CNVD database after querying ‘cancer’ term. It has a structure of data frame with 13
fields (Appendix 1F) providing the standard identificator of CNV, the information on biological origin,
localization in genome, specification of type, genes encompassed, eventual association with disorders,
experimental metadata and PubMed references.
4.3. Pre-processing
As already mentioned before, majority of Guan’s scripts uses the input files different than the original
provided within the challenge.  The pre-processing steps producing the referred documents are not
revealed by the author and they were inferred basing on scripts running further manipulations. The
reconstructed procedures was performed in R environment.
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6 https://www.cancergenomeinterpreter.org/home; Last accessed on 22/05/2017;
7 https://github.com/nkiip/GC2NMF/blob/master/0_origin_data/MGI_Gene.rpt; Last accessed on 22/05/2017;
4.2.1. Molecular Input
The objective of this step is to generate a set of six matrices corresponding to each  molecular data
source, with an unform organization. The respective matrices were saved in output  .txt files holding
the cell lines in columns and gene names in rows. Each of the original files required slightly different
treatments and procedures since they were not uniquely structured, they dealt with various problems
and demanded  specific filtrations. Note, that this pre-processing steps are valid for both- global and
local, molecular feature vectors.
RNA expression
While reading a  .csv source file to a data frame in R, the attention must be paid since some slight
automatic changes may occure in column and row names, as in the case of  expression data source.
The alterations took place for the cell line identificators strating with a numerical characters (they
received a prefix ‘X’) and for those containing hyphen sign within the name (hyphen turned dot).
Those alterations are not severe however prevents the correct recognition and so needed to be fixed.
After dealing with this feilure, the data frame was transposed to the requested standard conformation.
Finally, two instances holding NA values were bound to the matrix, preparing the entries for cell lines
for  which  expression  data  is  missing  (MDA-MB-175-VII,  NCI-H1437)  and  would  be  imputed
afterwards. 
Copy number
According to the CNV definition in Genomics of Drug Sensitivity in Cancer8, in order to consider a
gene as amplified it needs to hold at least 8 copies, while to be recognized as deleted – no copy can be
observed (the homozygous deletion, on both alleles). Following this interpretation, after reading a file
to R working space, only the valid abberations listed in original CNV data source were selected. In
order to avoid sex-dependent bias, additional filtering was performed and the alterations located on Y
chromosome were excluded.  Due to a large size of a data set  and difficulties in handling,  it  was
decided to  limit  the feature vector  and include only the CNVs located in dosage-sensitive  cancer
genes.  Those  were  determined  using  as  areference  the  file  outsourced  from  the  Copy  Number
Variation  in  Disease  (CNVD)  database  (4.2.2.  Copy  Number  Variation  in  Disease).  The  final
molecular  matrix  was  generated  and  the  data  was  binarized  assigning  to  each  gene  -  cell  line
combination a CNV status: ‘0’ corresponding to an absence of an aberration and ‘1’ standing for a
presence of 1 or more CNVs.
DNA sequence
Again,  preselection  of  relevant  genes  was  necessary  to  achieve  construction  of  realizable
implementation. Thus, only the mutations located in the driver genes were included in generation of
molecular matrix. This filtering was performed according to the file outsourced from the IntoGen
platform (4.2.1. IntOGen Mutations). Secondly, the irrelevant mutations were excluded by removal of
the instances assigned in the original source file with ‘PASSENGER/OTHER’ status in FATHMM
prediction,  and  those  identified  as  ‘Confirmed  somatic  variant’.  The  binary  matrix  was  created
similarly  to  CNV  case  -  by  assignment  of  the  mutation  status  to  each  gene  -  cell  line:  ‘0’
corresponding to an absence of a variant and ‘1’ standing for a presence of 1 or more mutations.
DNA methylation
The pre-processing of the methylation data source initialized with the assignment of the genes to the
probes and removel of instances without genetic annotation. As in the case of expression file, the cell
line names required corrections due to an automatic modifications introduced by R. Another issue –
presence of multi-gene probes,  was solved by multiplication of those instances by the number of
assigned genes and identification of each entry with a single gene annotation. The data frame was
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8 http://www.cancerrxgene.org/; Last accessed on 27/09/2017;
transposed to create a matrix with a standard structure. It was extended by three instances holding NA
values for missing cell lines (MDA-MB-175-VII, SW620, KMS-11) that served for future imputation.
CCLE RNA expression
In order to generate standard matrix summarizing expression data provided by CCLE, the instances in
original  file  were  assigned  with  the  genes  and  than  filtered  retaining  only  the  probes  with  the
annotations.  The  automatically  introduced  failures  in  cell  line  names  were  corrected  turning  the
identificators  consistent  with  the  Sanger  nomenclature.  The  data  was  subset  selecting  only  the
information related to cancer samples included in experiments. Three instances holding NA values
were introduced to the data frame, simulating the entries for missing cell lines: M14, MFM-223, NCI-
H3122. One of the genes, TTL, was found to be assigned to two different probes. The issue was
overcome by keeping a single instance with a median value.
CCLE copy number
After the reading of an original file to a data frame in R, a correction step was required to obtain
HGNC standarized cell line names. The instances corresponding to the cancer samples covered by the
challenge experiments were selected. As for CCLE expression data source, value for the same set of
cell  lines is unavailable:  M14, MFM-223, NCI-H3122. Thus, the molecular matrix is extended by
three entries holding NAs for posterior imputation.
Both  datasets  outsourced  from  CCLE  required  additional  pre-processing  step,  run  in  Python,
translating the internal nomenclature of sample to normalized primary cell line names. The conversion
was performed using as a reference .txt file outsourced from the CCLE platform, that contains cell-line
metadata from the cancer lines used in drug sensitivity screens.
4.2.2. Pharmacological Input
As one of the inputs for the mono-therapy feature vector serve the .csv files on the experimental results
of the single-compound assays (see 2.1.1. Pharmacological Data). The number of files storing the data
is higher than the number of drug pair - cell line combinations tested. The reason is that some of the
trials were repeated several times due to the problems in the performance. The accurate determination
of  experimental  file  of  origin  for  each  of  instances  was  a  challenge.  Different  approaches  were
undertaken:  determination  by  quality  score,  by  exclusion,  by  manual  curve-fitting  etc.  but  none
achieved to unequivocally identify the correct data source. The reproduction of dosage-response curve
fitting performed automatically with Combenefit software was not attained. Due to this issue, it was
decided to exclude the multi-source observations since those could introduce bias to the model. Thus,
123 of total  2199 drug pair  -  cell  line combinations were not  included in further processing,  and
feature vectors were constructed basing on 2076 unambiguous cases.
4.2.2. Compound Input
The input file holding information on chemical and structural drug characteristics (2.1.3. Compound
Data) deals with large amount of missing data: among 119 observations only 58 contain complete
information. Firstly, it was tempted to estimate the unavailable values basing on known measurements
of the most similar compounds, averaging them. However, this approach was not efficient and since
the  rfInput() function  of  R  provides  far  easier  solution  and  much  better  outcome,  it  become
implemented in script. No other pre-modelig steps were required for this data source.
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4.4. Modeling
As presented along pre-processing, the missing cell lines were introduced by appending the instances
filled with NA valaues.  This  approach is  afterwards  complemented by utilization of  additional  R
function – rfImpute(), just before building the model in order to simulate missing data using proximity
from  randomForest.  It  was  convinient  solution  since  both  maipulations  are  performed  in  R
environment but being jointly called from a Python script. This approach provided better results than
other experimented: imputation based on the averaging of values found in set of the most similar cell
lines. The similarity was determined by computing the distances between samples basing on available
molecular data. 
Originally the models were created using random forest algorithm and the approach was reproduced in
this work applying analogous  randomForest() function that belongs to the R package of the same
name [52]. It is an implementation of Breiman’s random forest algorithm established on Breiman and
Cutler’s original Fortran code, for both classification and regression problems. 
The number of trees grown was set to 200, following the original value of the argument. The first
variable in data was used as the response and resting are predictors.  The outcome variable was -
equally to the winning solution - normalized synergy score. The predictions were saved in  .txt files
with the structure identical to the standard proposed by Yuanfang Guan.
The baseline implementation exactly replicates the original steps of generation of partial and final
models, as well as the merging procedure. 
4.5. Evaluation Metrics
In order to evaluate the process of reproduction of winning solution and to assess the performance of
baseline implementation, the set of five different metrics were used. They all are used to determine the
goodness of fit of machine learning binary classification models. On the purpose of this work, the
following terminology was defined:
TP – number of true positive occurences,
FP – number of false positive occurences,
TN – number of true negative observations,
FN – number of false negative observations.
Matthews correlation coefficient (MCC)
Introduced  by  biochemist  Brian  W.  Matthews  [53],   the  MCC  metric  expresses  the  correlation
coefficient  estimated  for  the  true  observation  and  respective  predicted  value.  It  is  considered  as
reliable and balanced, having a special characteristics – being immune to differences in class sizes
[54]. The computation is performed basing on true and false positives and negatives (Eq. 4.1.). Its
value varies between -1 and +1, indicating in the first case the total inconsistency among predictions
and true values, and the pefect match – in the latter.  Value equal to zero suggests that the model
predictions are random.
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Matthews CorrelationCoefficient MCC= TP∗TN −FP∗FN
√(TP+FP )∗(TP+FN )∗(TN +FP)(TN +FN )
(4.1 .)
Sensitivity
This metric is also known as true positive rate, recall or probability of detection, depending on the
field where is applied. Its value represents the proportion of positive instances correctly dermined by
the model (Eq. 4.2.) [54]. The sensitivity can be interpreted as manner of quantification of avoiding of
false negatives.
Sensitivity= TP
TP+FN
(4.2 .)
Specificity
Another popular denomination of this metric is true negative rate and it is just opposite to sensitivity. It
expresses the proportion of negatives observations correctly indicated as such by the model (Eq. 4.3.)
[54]. Analogously, it provides a manner of quantification of avoiding the false positives.
Specificity= TN
TN +FP
(4.3 .)
Accuracy
The difference between a prediction and a true value can be expressed by accuracy. It is a ratio of all
observations  correctly  identified  by  model  total  number  of  instances  (Eq.  4.4.)  [54].  This  metric
reflects how close the estimations and observations are. Although, very informative, the accuracy is
sensitive to imbalances in classes sizes (that is a case of this work).
Accuracy= TP+TN
TP+TN +FP+FN
(4.4 .)
Balanced Accuracy
In  some  circumstances  accuracy  estimate  may  become  more  optimistic  then  the  reality  is.  To
overcome this issue more general metric may be used – balanced accuracy, that is simply the the
average accuracy obtained on either class (4.5.) [55].
Balanced Accuracy BAC=( TP
TP+FN
+ TN
TN+FP
)/2 (4.5 .)
4.6. Results
As mentioned in the introduction, after establishing the functional baseline implementation, the work
was  presented  to  a  small  public,  in  order  to  reflect  on  obtained  results  and  to  determine  further
directions. 
The  model  was  evaluated  including  the  specific  feature  vectors  one  by  one.  The  reason for  this
approach was to monitor the behavior after single inclusions and to have an idea on impact that each
of the specific data source has on the overall outcome. Moreover, the generation of predictions was a
time-consuming process, especially in the case of molecular data sources so the results were produced
gradually. The predictions created on local molecular feature vectors were never obtained throught the
baseline implementation – the run was killed after 2 weeks of processing. The results are summarized
in table 4.3. 
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Table 4.3. The partial result of evaluation of baseline implementation.
Model MCC Sensitivity Specificity ACC
Global Molecular 0.62637 0.63212 0.97828 0.95589
+ Chemical 0.61702 0.63007 0.97683 0.95449
+ Global Mono-therapy 0.73367 0.74397 0.98353 0.96804
+ File-counting 0.71282 0.71780 0.98297 0.96581
+ Local Mono-therapy 0.74383 0.76398 0.98304 0.96887
+ Local Molecular n/a n/a n/a n/a
Some conclusions may be formed basing on the data presented above. Firstly, apparently the inclusion
of chemical and file-counting data hurts the model causing a drop of all evaluation metrics. The best
scores  are  obtained  after  including  the  predictions  originated  from a  local  mono-therapy  feature
vectors – this step boost the model.
Generally the values are optimistically good. Investigating the reason of observation such high scores,
the failures and imperfections of the experiment design were found. It must be reminded that this
results were obtained testing a model on the original test set from the challenge. This fact implies that,
since true values had not been published yet, the implementation was evaluated using as a reference
matrix the final outcomes submitted by Yuanfang Guan, assumed as a ‘true’ on the purpose of this
work. Moreover, the assessment was performed including all the possible combinations, while the ‘0’
values indicating non-synergic effect were assigned also to the unknown cases. That means that the
number of true negative is falsely elevated and the values obtained for specificity proves it.
According to this conclusions it was decided to on the purpose of this project construct a new training
and test sets, from the available and known challenge data. The new subsets had to reconstruct the
original circumnstances what in practice meant that they had to be totally disjoint on drug pairs. They
were balanced in size, holding 30% and 70% of data by respectively test and training sets.
It  was  decided  that  in  order  to  obtain  reliable  evaluation  scores  the  model  assessment  must  be
performed exclusively on the test  instances,  neverthless that  an entire  matrix  holding all  possible
combinations  is  produced.  The alterations were introduced into the script  and the unknown cases
although still present in prediction matrix, they become to be assigned with NA values.
Furthermore, three directions of future work to be developed were defined:
1) Feature selection;
2) Alternative models;
3) Predictions-merging equation.
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5. Model Improvement
Since the molecular data source deals with abundance of variables, the main point of the focus was to
reduce the number of features included in the model selecting only the informative ones. The aim was
also to determine the most important variables because those could be the potential biomarkers.
The baseline implementation follows the winning solution building the models with Random Forests
algorithm. However there is no evidence provided by the Yuanfang Guan that this approach is the most
proper for the challenge problem. In this work an efforts were made to test the performance with two
others  methods:  Support  Vector  Machine  (SVM)  and  Multivariate  Adaptive  Regression  Splines
(MARS).
Moreover,  the  attempts  were also directed at  establishment of optimal merging equation since no
information is available confirming that the version implemented in original script is the most accurate
one. The establishment of used coefficients is not reported in the submission documentation, neither in
PERL scripts.
5.1. Feature Selection
Feature selection in machine learning approaches is very often a requisite step for model building.
Nowadays it is necessary to deal with large datasets with many variables since the production of the
data is rather not an issue anymore. This fact brings two complications:
1) most of the variables are not relevant, they do not contribute to the model or even can cause a
decrease of accuracy. Those preferably should not be included in the feature set at all.
2) high technical requirements. Large datasets are demanding to deal with  because they highly slow
down the process and may turn it impossible to run in reasonable time. Also they need many resources
that are often unreachable for one.
Thus it  is preferable to select possibly the smallest set of variables that would ensure the optimal
results  and  manageable  data  size.  It  is  necessary  to  find  an  approach  that  would  identify  all  of
attributes with their relevance to the model, indicating those that shall be retained and included in the
process.
5.1.1. Tools
Least Absolute Shrinkage and Selection Operator
Least  Absolute  Shrinkage  and  Selection  Operator  (LASSO)  is  a  supervised  regression  machine
learning method using a shrinkage [56]. The approach generates simple and sparse models, especially
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convenient in the case of high multicollinearity among variables where only most important features
are selected.
The principle of the lasso is shrinkage that is in general bringing down of values to some central point.
Since the method requires a constant threshold defining the maximum sum of the absolute model
parameters, it implies that some variable coefficients would be reduced to 0. In the effect the shrunk
model  will  include  fewer  features,  those for  which the  coefficients  remain  different  from 0.  The
features selection step allows to determine the predictors highly associated with the respond variable
and minimizing the error related to the outcome. Also, due to such a simplification, the interpretation
of model becomes improved and user-friendly. The lasso is able to provide models of high accuracy
and  is  especially  useful  when  there  are  relatively  low number  of  instances  and  high  number  of
predictors.
The simplicity of lasso regression is also in a tuning by a single parameter λ, that controls strength of
the penalty. The higher value of parameter, the more reduced model is obtained what means that more
coefficients are turned to 0.
Boruta
Boruta is an  ‘all-relevant’ wrapper algorithm for feature selection through the variable importance
measure (VIM) [57]. It identifies variables correlated with the response more than random ones. By
default it is built around the random forest classification but the function is able to work with any other
method for which the importance metric is available. In short,  Boruta selects the relevant features
comparing their original importance with the random estimations from permuted copies. The search is
run top-down and irrelevant attributes are eliminated gradually.
The idea of approach was inspired on RFs methodology where the randomness is introduced to the
analysed system and the results are obtained from an enseble of samples picked by chance [58]. In this
way the added randomness reduces the tricking influence of casual variations and non significative
correlations, and meanwhile it is supposed to expose the truly important features. The main steps of
algorithm include: (1) The system is enriched with extra copies of all attributes (so called  shadow
features). (2) The added variables are shuffled removing the random correlations. (3) The default RFs
classification algorithm (applied here due to its quickness, no need for parameter tunning and the
output of numerical estimation of importance) is run and the VIM values are obtained for enriched
data (mean decrease accuracy by default). (4) For each attribute, the Z- score is compared with the
maximum  value observed among all its shadow features. If scoring significantly higher, the variable is
recognized as important  and kept  in data system, otherwise it  is  assigned as non-informative and
permanently  eliminated.  (5)  The  procedure  is  repeated  untill  all  the  attributes  are  identified  with
confirmation/rejection status or when the limit of RFs runs is reached.
5.1.2. Methods
Overall, the establishing of feature selection approach for molecular data sources was one of the most
laborious stages of the project. The workflow was changed and adjusted along the progress. The final
procedure  is  visualized  graphically  on  figure  5.1.  and  described  in  details  within  the  following
sections.
The various attempts were performed to define the set of the most informative features with Boruta
algorithm.  However,  the  methodology  was  found  inconvenient  in  this  work  due  to  inconvinient
relative values expressing the importance and low reproducibility of results with such a high number
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of variables. One of the experiments run with this methodology had as an aim the establishment of
significance order for all molecular branches. In the result the global models built on mono-therapy
and molecular data sources were identified as the most relative. Next in the order were their local
adaptations, after - the counting-file branch, and finally determined as the less important – chemical
data source. Those indications were taken into consideration while optimizing and establishing new
values of coefficients in equation merging the branches. 
Figure 5.1. Workflow of feature selection performed on molecular data sources applying Lasso algorithm.
Pre-processing
To start, for different molecular data sources the separate files are prepared in Python. The process is
similar  to one implemented in baseline approach.  The only difference is that  instead of assigning
feature vectors to cell lines [CL], they are directly attributed to corresponding response values, i.e.
normalized synergy scores that are going to be predicted by afterwards created models.  Thus, the .txt
files produced for molecular data sources follow the standard structure where first column of each line
is an outcome value and the next – predictor variables determining state of each particular gene. The
features selection is performed for five of six sources: gene expression, CNVs, mutations and two
CCLE outsourced files. The methylation is excluded due to the size of dataset that turns procedure
unrealizable in acceptable time.
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Selection
This step is realized in R and processes each of molecular information source separately. It starts with
data partitioning and creating of 10 disjoint folds of the same size. In each iteration one of subsets
serves  as  test  set  while  the  rest  makes the collection of  training sets.  The model  is  created with
glmnet() function of a R package of the same name [59], which fits a generalized linear model (GLM)
with lasso regularization since a parameter alpha is set to ‘1’. The fitting is realized via penalized
maximum likelihood and the sets of estimations are computed for different values of the regularization
parameter lambda. Next a grid of the predictions is produced for a range of considered λ. Those are
compared with the true values in a test set and for each parameter λ a mean squared error (MSE) is
calculated. 
After terminating a loop, a data frame summarizing runs for all data folds is generated. Each run is
characterized with a list of lambda parameters and corresponding MSE values. In order to select the
most advantageous model, the .png image is created with a graph summarizing the runs (Figure 5.2.).
Each curve plots the lambda as a function of mean squared error: MSE = f(λ). The lambda parameter
values are presented on X-axis while computed corresponding mean squared error – on Y-axis. The
visual inspection of a graph allows estimation of a parameter λ that potentially could bring the most
promising result.
Figure 5.2. Graphical summary of example predictions produced by lasso models for gene expression data .
Each curve plots the mean squared error as a function of  λ:  MSE = f(λ). The lambda parameter values are
presented on X-axis while computed corresponding mean squared error – on Y-axis.
The graphical visualization prepared for each molecular data set allows establishing of a final set of
lambda parameters (Table 5.1.).
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Table 5.1. Values of lambda parameter established after the visual inspection of summarizing plots.
Gene expression CNVs Mutations CCLE expression CCLE CNVs
λ 2.00 1.50 1.25 2.00 1.00
Subsequently, an entire data set is divided to training and test set containing  respectively 70% and
30% of  original  information.  Again a lasso model  is  prepared but  this  time with a determined λ
parameter. Having a lambda fixed it is possible to obtain the coefficients assigned to variables and
determining their  contribution to  the  selected model.  At  this  point  the genes  that  has coefficients
different from 0 are considered as important for obtaining possibly the best predictions. The set of
three steps  described above:  1)  data  partition,  2)  fixed λ model  building and 3) determination of
informative variables,  they are repeated in 60 independent  runs.  The lists  of  selected features are
merged and for each instance the frequency of occurence is calculated. 
It is assumed that if a gene appears repeatedly (for example 50 times) within 60 runs, this fact shall
reflect its importance in the model. Contrary, if some instance was observed only once or two times, it
can be clearly presumed as an occurence by chance. According to this logic, a particular threshold that
determines a frequency of relevant events, needed to be established.
The threshold is set to 30 for all of data sources, after plotting mean squared error as a function of a
number of features:  MSE = f(#features), for all the selection of produced models (Figure 5.3). The
number of variables in model is presented on X-axis while corresponding mean squared error – on Y-
axis. 
Figure 5.3. Visualization of predictions produced by lasso model on molecular data with features selected
according to the established workflow. Each curve plots the mean squared error as a function of number of
features: MSE = f(#features). The numbers of features are presented on X-axis while computed corresponding
mean squared error – on Y-axis.
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As the graph suggests, there is no point in building a model on more than 50 features – inclusion of
next variables does not bring an improvement. Thus, defined cut off on frequency allows selecting
from each data source less than 50 variables as summarized at the table 7.2.
Table 5.2. Summary of the number of features selected on each data source with lasso algorithm, with the
frequency of occurance at least 30 per 60 runs.
Gene expression CNVs Mutations CCLE expression CCLE CNVs
# features 31 33 29 25 47
The figure  5.4.  summarizes the  result  of  10-fold cross  validation run on model  with a frequency
threshold set  to  30.  Light  blue plots  correspond to each run while  navy blue curve averages  the
outcomes. According to the graph, the lambda parameter with a value around 2 shall provide results
with reduced MSE.
Figure 5.4. Visualization of predictions produced by lasso model on molecular data with features selected
according to the established workflow. Each curve plots the mean squared error as a function of lambda: MSE
= f(λ). The lambda parameter values are presented on X-axis while computed corresponding mean squared
error – on Y-axis.
Next,  the  produced gene  lists  are  merged in  unspecified  order  and for  each  partially  normalized
synergy score a feature vector holding in total 165 variables is created. Again, the generated dataset is
partitioned into 10 disjoint folds, where in each iteration one of those serves as test set while others –
as collection of training sets. The lasso models are created without fixed lambda parameter. The grid is
generated that holds for each run: λ values, corresponding mean squared errors and respective number
of features entering the particular model. This data frame serves for final determination of lambda.
Thus, the value of parameter is fixed to a maximum λ providing a model built on 60 or less features.
Obtaining coefficients assigned to variables for defined lambda in the last created lasso model, the list
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of potentially most important features is defined. This collection is included in pre-processing step of
global molecular branch as a filter on already simulated feature vectors, allowing reduction of their
size and  selection only of variables detected as informative.
5.1.3. Evaluation
It was decided to observe the behavior of an established feature selection workflow in order to confirm
its ability and productivity by graphical visualizations. Particularly it was pretended to verify if MSE
and lambda parameter values obtained during the process of establishing a feature selection workflow
are reliable or rather could be observed by chance. The simulation generating 500 lasso models with
selected features allows inspection of distribution of minimum MSE produced within all the runs and
their corresponding lambda parameters, as presented on the figures 5.5. and 5.6. respectively.
Figure 5.5. Histogram of minimum MSE values obtained in simulation of 500 runs.
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Figure 5.6. Histogram of lambda parameter obtained for minimum MSE values produced in simulation of 500
runs.
Both graphs confirm that small models obtained during the establishing process somehow reflected the
general trend in the data and so it can be relied on.
5.2. Regression Modeling
5.2.1. Tools
Support Vector Machines
Support  Vector  Machines  (SVM)  is  a  non-linear  supervised  learning  algorithm  applicable  in
classification and regression problems. Although it was developed in the 1990s by Corinna Cortes and
Vladimir  Vapnik  [60],  it  still  continues  to  be  one  of  the  most  popular  and  efficient  methods,
recommended especially for data with numerous variables.  
The idea of SVM is to create a separating optimal hyperplane (or a set of those in high-dimensional
space) that would - perfectly - to any given instance assign a correct category. The unique and the best
solution is found for the maximum margin of the training set (convex optimization – no local minima).
Often the hyperplane cannot be defined by a linear equation and the kernel trick must be applied. That
is, using nonlinear mapping, the original data is transformed into a higher dimensional space, in such a
way that allows creating linear decision boundary within instances. Among most common examples of
kernel functions applied in practice, the polynomial, radial or sigmoid are found.
In this work SVM was experimented as a machine learning methodology in a process of optimization.
It  was  chosen  due  to  its  robustness,  high prediction  accuracy and low overfitting.  Although it  is
computationally expensive and slow, still it is expected to exceed the performance of RFs [61][62].
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Multivariate Adaptive Regression Splines
Multivariate Adaptive Regression Splines (MARS) is a nonparametric supervised learning algorithm
for regression and  classification problems, that does not require any assumption about relationship
between predictors and the dependent variable. The existing correlations and functions are derived on
the basis of  the original  data.  The general  idea is to divide total  data space and obtain groups of
instances for which the local regression equation may be determined [63][64]. This is s reason why
MARS  is  suitable  for  large  inputs,  overcoming  limitations  of  many  other  machine  learning
methodologies.
The  algorithm  includes  following  steps:  (1)  generation  of  simple  model  with  the  constant  basis
function; (2) exploration of basis function space, with all possible variables and knots; (3) selection of
solutions that provide the best model (those with minimal prediction error); (4) repetition of search-
select  steps  (3 and 4)  until  the  pre-defined complexity  limit  is  achieved;  (5)  pruning  eliminating
solutions with the least contribution to the total goodness of model [65].
MARS  being  very  promising,  especially  in  complex  data  mining  problems,  was  chosen  to  be
experimented in the model optimization and compared to the RFs and SVMs performance.
5.2.2. Methods
Regarding to  the Support  Vector  Machine,  it  generates  the models  using  svm() function provided
within ‘e1071’ R package [66], that is based on implementation by Chang et al. [67]. In general, the
concept follows a sequence of steps: 
1) Class separation – having two classes, the optimal separating hyperplane is established,
always aiming the maximization of the margin between the closest instances of the two sets;
2) Dealing with overlapping classes – the instances that are incorrectly classified with built
hyperplane are weighted down in order to minimize their impact;
3) Handling the nonlinearity – if the instances initially are not linearly separable, they are
projected via kernel techniques into an higher-dimensional space,  allowing construction of
linear separator;
4) Problem solution – known techniques are adopted to solve a final quadratic optimization
problem. [60]
An  another  experiments  were  carried  implementing  a  Multivariate  Adaptive  Regression  Splines
(MARS) approach for building a model. The earth() function from R package of the same name [68]
was utilized and a regression model was generated basing on Friedman’s techniques [69].
Although both algorithms surpass a Random Forest approach, always the SVM methodology is in a
favour and brings the improvement into the final model.
5.3. Prediction-merging equation
The merging step reconstructed on original implementation of Yuanfang Guan, follows the general
equation presented already in section 3.5. and recalled below:
Thus, the originally applied coefficients are set to 0.25 for four branches: global and local molecular,
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PFinal  = (PGlobalMolecular+2∗PGlobalMonotherapy+PChemical+PFileCounting+PLocalMolecular+2∗P LocalMonotherapy)/4
chemical and file-counting, while  they are equal to 0.5 for both mono-therapy data sources. In this
work  an  attempts  were  undertaken  to  optimize  the  merging  equation  and  different  versions  of
computations were performed varying coefficient values between 0 and 2, in various combinations.
Observation of the parameters and their final outcomes for chosen SVM model, allows establishing of
the most efficient values. The identified coefficients are summarized in the optimized equation 7.1.
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P Final  = 
(2∗PGlobalMolecular+0.25∗PGlobalMonotherapy+0.25∗PChemical+0.25∗P FileCounting+0∗PLocalMolecular+0.25∗PLocalMonotherapy )
(5.1 .)
6. Results & Discussion
Although there is a test set provided within the challenge, it could not be utilized as such in this work
since the true values are unavailable. Thus, it was decided to independently create training and test
subsets from a data with known synergy scores. The aim was to reproduce as accurately as possible
the original training and test environment and the relation between two subsets. 
It was observed that provided training and test drug pairs are disjoint – none of the training compound
combinations is present in a test set. Regarding to the size, the test set is approximately two times
smaller than the other. While it is understandable to follow the first indication and mimic it creating
cohorts independent in drug pairs, it was found unreasonable to reproduce the size proportions. The
general rule of machine learning was followed and standard partition was performed: ~ 70% of data
became training set and resting ~ 30% - a test. 
In the effect, the final implementation was trained on the dataset of 4434 observations encompassing
378 unique drug pairs, and tested on 1898 cases with 161 unique compound combinations.
Established feature selection workflow allowed production of a list with molecular variables identified
as informative and contributing to the model. In total, 75 features were determined, including between
8 and 19 from particular data sources as summarized in the table 6.1. The total list of selected features
is provided in Appendix A.
Table 6.1. Summary of the final number of features selected on each data source with established and applied
feature selection workflow.
Gene expression CNVs Mutations CCLE expression CCLE CNVs
# features 17 12 19 8 19
The final  optimized implementation was run using as a  model  building algorithm Support  Vector
Machine within ‘e1071’ R package, and merging the branch models according to the equation 7.1. In
the table 6.2. the final evaluation results are presented, following the metrics defined in section 4.4. 
Table  6.2.  The  final  result  of  evaluation  of  optimized  implementation.  Values  are  averages  from  three
identical and individual runs.
MCC Sensitivity Specificity ACC BAC
0.985 0.708 0.789 0.631 0.847
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Those values can be referred to the evaluation results obtained in 3rd submission of original
implementation by Yuanfang Guan. The scores recalled in table 6.3. are published in a DREAM
challenge website, section 4.2 – Subchallenge 29. For the final submission only the BAC metric
is known: 0.61, indicating that the performance was slightly weaker than for a leaderboard.
Table  6.3.  The  evaluation  scores  obtained  by  Yuanfang  Guan  in  the  3rd  submission,  performed  on  the
subchallenge 2 leaderboard.
MCC Sensitivity Specificity ACC BAC
0.27 0.71 0.6 0.35 0.66
According to presented metrics, the performance of optimized implementation being an objective of
this work, provides better results than the original inspiration approach.
The list of features selected in process of optimization brought an interesting matter to explore more
and study.  The  selection  of  75  variables  includes  3  genes  that  are  relative  to  model  due  to  two
molecular characteristics each (Table 6.4.). Those and more 11 genes of the final selection, are targets
according to the list provided within the challenge.
Table 6.4. Genes within features selected in optimization process which contribute to final model with more
than  one  molecular  characteristics.  The  aliases  are  determined  according  to  GeneCards  Human  Gene
Database (www.genecards.org). 
Gene Molecular Characteristic Aliases
ATR mutation & expression ATR Serine/Threonine Kinas
MAP2K1 expression & CCLE expression Mitogen-Activated Protein Kinase 1
XIAP expression & CCLE CNV X-Linked Inhibitor Of Apoptosis, E3 Ubiquitin Protein Ligase
One  of  the  most  broad  in  terms  of  resources  included platform is  a  REACTOME10 –  a  Curated
Pathway Database. It is based on knowledge provided in databases as NCBI Gene, Ensembl, UniProt,
UCSC Genome Browser, KEGG Compound, ChEBI, PubMed and GeneOntology [70]. Its aim is to
support the research on genome and systems biology while visualizing, interpreting and analysing a
pathway information. It delivers to bioinformatic community a user-friendly and intuitive tools [71].
Submitting the list  of  genes selected throught the  final  workflow, the  analysis of  overrepresented
pathways was obtained. According to the results, the cytokine signalling in immune system and most
specifically defining - signalling by Interleukins, are the most frequently assigned among the provided
instances, being represented by respectively 17 and 15 entities. However, apparently there is no further
pattern found – the genes involve various pathways, without special trends and preferences.
The STRING11 is an open access database with a knowledge on protein-protein interactions and was
utilized to create a visualization of a functional protein association network for  a list of 72 unique
genes from final selection (Figure 6.1.). Instances underlined in red are the target genes, in blue –
genes further analysed as potential biomarkers.  The associations are established on direct (physical)
and indirect (functional) evidences. Connections are inferred from computational predictions, analogy
between organisms and transferred from other (primary) data sources [72]. As could be expected, the
target genes are located within the ligations in generated network, with numerous connections and
interactions. This is understandable since the knowledge on those is already well established and they
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9 https://www.synapse.org/#!Synapse:syn4231880/wiki/390507; Last accessed on 26/09/2017;
10 http://reactomerelease.oicr.on.ca/; Last accessed on 27/09/2017;
11 https://string-db.org/; Last accessed on 27/09/2017;
share common processes related to cancer. But the point of interest are isolated cases because those
hold a potential to be undiscovered tumor biomarkers. It was decided to perform an additional analysis
of three genes that are not targets, that presented the highest frequency of occurence and that although
appear in STRING network, they have no connection established.
Figure 6.1. Functional protein association network created with STRING after submitting a list of 72 unique 
genes from final selection. Instances underlined in red are the target genes, in blue – genes further analysed as
potential biomarkers.
The first of cases selected to be explored is tetratricopeptide repeat domain 40 or shortly TTC40 gene.
Its mutation characteristics are indicated as informative within the selected features list.  It  is  also
known as CFAP46 - Cilia And Flagella Associated Protein 46. According to UniProtKB/Swiss-Prot it
makes a part of the central apparatus of the cilium axoneme and plays a role in cilium movement.
There is not much information found on this gene in the scientific literature. In a study from 2014
there  was  an  association  detected  between  hypermethylation  of  TTC40  and  nasopharyngeal
carcinoma. The authors identified a CpG island at 10q26.3 locus to be frequently methylated in cancer
samples and to be  correlated with transcriptional silencing of this previously undetermined gene [73].
TTC40 is not included in the driver gene list used in this work as described before. Since there exist
among the scientific publications some indication on its association with the tumor, it may confirm the
hypothesis of being a potential candidate for the cancer.
The CNV status of GSTT1 is also found to be relative to build model. This gene encodes glutathione
S-transferase theta 1 protein which belongs to a family initailizing the detoxification by catalyzing the
conjugation of reduced glutathione to a range of electrophilic and hydrophobic composites that are
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12 http://www.uniprot.org/; Laste accessed on 27/09/2017;
potential toxins  [74]. It is located on chromosome 22q11.2 and the product enzyme is expressed in
human erythrocytes. The theta class of glutathione S-transferases is associated with carcinogenesis.
Particularly  GSTT1  is  found  to  contribute  to  larynx  cancer  and  mutagen  sensitivity  related  to
nasopharyngeal and colorectal carcinomas (http://www.genecards.org). This gene is haplotype-specific
and is  referred as absent  in 38% of population.  The observation of GSTT1 phenotypes in a large
family suggests  that  the  gene is  passed  through generations  according  to  mendelian  intermediary
inheritance, where due to the gene-dosage effect in the presence of 2 functional alleles the enzyme
expression is doubled [75].
There are various studies indicating GSTT1 contribution to detoxification processes.  Patients with
nonfunctionall  GSTT1 allele have frequently decreased ability to metabolize environmental  and/or
endogenous carcinogens or toxins and may be at risk of developing pathologies. In the work of Chen
et  al.  [76],  the  GSTT1  null  genotype  was  observed  among  46%  of  analysed  cases  with
myelodysplastic syndromes (MDS) while in the cancer-free controls – only among 16%. There are
associations found also with occurance of aplastic anemia  [77] and with reduction in birth weight
among smoking mothers [78]. The explanation behind is common - a reduced capability to deal with
toxic factors.
According to the references, the GSTT1 gene is a strong biomarker candidate. Its association with a
cancer  is  broadly  observed  and  documented  but  still  there  should  be  performed  extra  studies  to
confirm its  predictive power. 
SKAP1, Src Kinase Associated Phosphoprotein 1, is identified as informative due to its CNV status.
Its  product  is a T cell  adaptor protein that  belongs to a class of intracellular  compounds carrying
domains with ability to recruit additional proteins [79]. Those molecules are incapable to perform any
intrinsic enzymatic activity and play a role in T cell receptor and Ras signaling pathways. SKAP1 is
responsible for for optimal conjugation between T-cells and antigen-presenting cells by enhancing the
clustering of ITGAL integrin on the surface of T-cells. Moreover it may contribute to a high affinity
immunoglobulin epsilon receptor signaling in mast cells. The only indication on the  association of
SKAP1 with a cancer found at this moment, is a list of dosage-sensitive cancer genes provided by
CNVD and used in pre-processing of CNV data source.  Thus,  its  potential  on being a biomarker
candidate requires much further investigations. 
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7. Conclusions
The  practical  aim  of  this  project,  namely  the  implementation  of  an  hybrid  machine  learning
methodology was achieved. The approach applied in the 2016 DREAM Challenge winning solution by
Yuanfang Guan was explored and comprehended. As the result of this work, the functional baseline
script  flow  reproducing the  original  methodology  was  produced  using  R  and  Python  languages.
Moreover,  due  to  the  optimizing  manipulations,  the  imlementation  was  successfully  improved
providing higher evaluation scores.
Comparing a performance of different machine learning algorithms permitted gaining a practice and
familiarity  with  the  methodologies.  The  preferable  approach  for  this  prediction  problem  was
identified, that is Support Vector Machine. Regarding to the merging equation, the optimization step
brought improvement by the re-establishment of parameters.  Although there was a trend observed
among the efficiency of methods and coefficients applied, the detected variances were not critical.
However,  according to the common law,  through the small  changes the final  great  result  may be
obtained.
The  feature  selection  procedure  allowed  obtaining  a  list  of  potential  cancer  biomarkers.  Those
candidates varies in the level of confidence depending in general on the information available, studies
carried on the genes etc.  Thus,  the  weaker preferably require much more profound and extended
verifications, including a high number of experimental analysis.
Finally the initial aims that caused this work to arise were successfully accomplished. The process of
implementation development guaranteed high training on machine learning methods, broadening the
knowledge  on  techniques  and  algorithms.  The  approach  of  multi-source  data  integration  was
successfully explored opening new possibilities of application in a range of pharmacological modeling
problems.
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Appendix 1
Specification of the files
This appendix provides tables presenting structure of the files organizing a data used in this work.
A. Pharmacological Data
The following table reflects the structure of the .csv file recording pharmacological data.
Column name Data type Description and comments on nomenclature Example
CELL_LINE Factor Unique and common normalised cell line identifier; BT-20
COMPOUND_A Factor
Unique and anonymised drug A identifier; Name indicates primary target 
of action and specifies the version of pharmaceutical;
AKT
COMPOUND_B Factor
Unique and anonymised drug B identifier; Name indicates primary target 
of action and specifies the version of pharmaceutical;
ADAM17
MAX_CONC_A Numeric
The maximum concentration of compound A tested in experiments;
Expressed in μM;
1
MAX_CONC_B Numeric
The maximum concentration of compound B tested in experiments;
Expressed in μM;
75
IC50_A Numeric
The concentration of compound A causing 50% of the maximum cell 
death; Expressed in μM;
1
H_A Numeric The slope of the curve fit (Hill model) for compound A 0.8090022
Einf_A Numeric
Maximum cells killed obtained with compound A; Expressed in 
percentage;
59.1224363
IC50_B Numeric
The concentration of compound B causing 50% of the maximum cell 
death; Expressed in μM;
9.63971363
H_B Numeric The slope of the curve fit (Hill model) for compound B 0.7579769
Einf_B Numeric
Maximum cells killed obtained with compound B; Expressed in 
percentage;
91.5934245
SYNERGY_SCORE Numeric Computed total synergy score for A- B drug pair and cell line combination 29.54039
QA Numeric
Quality Assesment;
‘0’ for assay with missing data; ‘-1’ for assay with ≥ 1 record of cell kill 
above 125%; ‘-2’ for assay with ≥ 1 record of cell kill below -10%; ‘-3’ for
the assay with the difference between smoothed and non-smoothed fit 
above 25%; ‘1’ for assay for which no abnormalities were detected;
1
COMBINATION_I
D
Factor
The identifier of drug pair;
Name combining the identifiers of drug A and B, joining them by ’.’ in 
alphabetical order;
ADAM17.
AKT
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B. Copy Number Variants Data
The following table reflects the structure of the .csv file recording data on CNVs.
Column name Data type Description and comments on nomenclature Example
cell_line_name Factor Unique and common normalised cell line identifier; 22RV1
gene Factor Normalised gene identifier, according to COSMIC annotation (mostly equivalent to HGNC nomenclature); ZZZ3
chr_GRCh38 Factor Chromosomal localization of CNV according to GRCh38; 1
gene_start_GRCh38 Numeric Coordinates of the gene’s start according to GRCh38; 7756565
gene_end_GRCh38 Numeric Coordinates of the gene’s stop according to GRCh38; 7763335
max_cn_GRCh38 Numeric
Maximum number of copies of gene (the coding sequence) found within the genome; ‘-’ for unknown values; ‘-1’ for 
undetermined value;
2
min_cn_GRCh38 Numeric
Minimum number of copies of gene (the coding sequence) found within the genome; ‘-’ for unknown values; ‘-1’ for 
undetermined value;
2
zygosity_GRCh38 Factor
Identifies if the copies of gene sequence are continuous or interrupted; ‘D’ for the copied sequence encompassing > 1 
genomic segment; ‘-’ for the copies identified wihin the single genomic segment;
H
disruption_status Factor
Determines if alleles are equal or different;‘H’ for heterozygous repetitions; ‘L’ for any occurance of LOH (loss of 
heterozygosity) ; ‘0’ for the total homozygous deletion;
D
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C. DNA Sequencing Data
The following table reflects the structure of the .csv file recording data on mutations.
Column name Data type Description and comments on nomenclature Example
Gene.name Factor Normalised gene identifier; According to COSMIC annotation (mostly equivalent to HGNC nomenclature); CTNNB1
Accession.Number Factor Unique identifier of transcript; According to Ensembl norms; ENST00000349496
Gene.CDS.length Numeric Length of the gene; The unit used: base pair; 2346
HGNC.ID Numeric Standarized identifier of gene (if exists); According to the HUGO Gene Nomenclature Committee norms; 2514
cell_line_name Factor Unique and common normalised cell line identifier; SW48
ID_sample Numeric Unique identifier of sample; According to COSMIC identification standards; 909751
ID_tumour Numeric Unique identifier of tumour; According to COSMIC identification standards; 827235
Primary.site Factor The type of sample’s tissue of origin; According to COSMIC identification standards; large_intestine
Site.subtype Factor
The subtype of the sample’s tissue of origin; According to COSMIC identification standards; According to 
COSMIC identification standards;
colon
Primary.histology Factor The type of sample’s tissue of origin; According to histological classification norms; carcinoma
Histology.subtype Factor The subtype of the sample’s tissue of origin; According to histological classification norms; adenocarcinoma
Genome.wide.screen Logical Identifies if the mutation comes from wide genome/exome sequencing study y
Mutation.ID Factor Unique mutation identifier (according to COSMIC classification standard) COSM5673
Mutation.CDS Factor
The specification of the mutation on the nucleotide level; The notation accoring to the standards of the 
Human Genome Variation Society;
c.98C>A
Mutation.AA Factor
The specification of the change on the peptide level provoked by the mutation; The notation accoring to the 
standards of the Human Genome Variation Society;
p.533Y
Mutation.Description Factor The specification of the type of mutation; Among others: insertion, deletion, substitution, complex etc.
Substitution –
Missense
Mutation.zygosity Factor
The status of zygosity of mutation; 'het’ for mutations reported as heterozygous; ‘hom’ for mutations 
reported as homozygous;
het
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GRCh Numeric Specification of the reference human genome build; '37’ for GRCh37/Hg19; ‘38’ for GRCh38/Hg38; 38
Mutation.Genome.position Factor The coordinates of mutations defining localization ath the genome 3:412240-412246
strand Factor Orientation of the strand; '+’ for positive/forward/sense strand; ‘-’ for negative/reverse/antisense strand; +
SNP Factor
Identifies if  mutation is recognized as SNP; 'y' for SNPs recognized within the 1000 genomes project; ‘n’ 
for apparently neutral SNPs according to dbSNP and to a panel of 378 normal (non-cancer) samples from 
Sanger CGP sequencing;
n
FATHMM.prediction Factor
FATHMM (Functional Analysis through Hidden Markov Models) descriptor defining pathogenicity of 
mutation; 'Cancer’ or ‘Damaging’ for mutations considered as pathogenic; ‘Passenger’, ‘Tolerated’ or 
‘Others’ for apparently neutral mutations;
CANCER
Mutation.Somatic.status Factor
The specification of the evidence on somatic status of the mutation; 'Confirmed somatic variant’ for 
mutation experimentally vlidated to be somatic in cancer and control cells; ‘Reported in another cancer 
sample as somatic’ when the experimental validation did not provide an evidence but the mutation was 
reported in the literature as somatic; ‘Variant of unknown origin’ for a mutation that was verified to be 
somatic solely in the tumour sample;
Confirmed somatic
variant
Pubmed_PMID Numeric The identifier corresponding to the publications involving the sample; According to PUBMED annotation; NA
ID_STUDY Numeric The identifiers of studies engaging the sample NA
Institute Factor The unit providing the sample
American Type
Culture Collection
Institute.Address Factor Address of the unit providing the sample P.O. Box 19,Manassas, USA
Catalogue.Number Factor Internal identifier of the sample assigned in the unit CCL-231
Sample.source Factor The biological origin of the sample collected Cell-line
Tumour.origin Factor
The specification of the neoplastic origin of the collected sample; 'primary’ for the sample collected at the 
anatomical site of tumour outset; ‘metastasis’ for the sample collected at the secondary localizations, 
different than where the tumour progression began ; ‘NS’ for not specified origin;
primary
Age Numeric Age of the individual 82
Comments Factor Additional information related to sample Grade:II,Stage:II
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D. Compound Data
The following table reflects the structure of the .txt file listening the chemical and structural characteristics of 119 unique compounds.
Column name Data type Description and comments on nomenclature Example
ChallengeName Factor
Unique and anonymised drug A identifier; Name indicates primary target of action and specifies the 
version of pharmaceutical;
Carboplatin
Target
(Official Symbol) Factor
List of all putative targets; Gene names according to the HGNC annotation; DNA
HBA
Numeric
H-bond acceptors; The number of oxygen and nitrogen atoms; Indicates polarity of chemical; 6
cLogP
Numeric
Calculated octanol-water partition coefficient; Determines solubility of the chemical; -2.34
HBD
Numeric
H-bond donors; The number of groups -NH or -OH carring extra hydrogen atom; Indicates polarity of 
chemical;
4
Lipinski
Numeric
Lipinski rule of 5: The number of fulfilled rules among: HBA ≤ 10, HBD ≤ 5, cLogP ≤ 5 and MW < 
500 Da ; Determines drug-likeliness of chemical;
0
SMILES or PubChem ID Factor
The additional compound specification (if available); According to  the Simplified Molecular Input 
Line Entry Specification (SMILES) or to PubChem annotation;
C1CC2(C1)C(=O)O[Pt]
(OC2=O)(N)N
MW Numeric Molecular weight; Expressed in g/mol; 369.2
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E. Driver Genes Data
The following table reflects the structure of the .csv file listening the 498 cancer drivers and their characteristics downloaded from IntOGen platform.
Column name Data type Description and comments on nomenclature Example
geneHGNCsymbol Factor Gene names according to the HGNC annotation; ABL2
Driver_type
Factor
Specification of alteration type; ‘CNA’ for Copy Number Alteration ; ‘FUSION’ for hybrid gene formed 
from previously separated genes; ‘MUTATION’ for permanent alteration of the nucleotide sequence;
FUSION
Role Factor
The effect of the gene alteration; ‘A’ for altered gene product that acts antagonistically to the wild-type 
allele; ‘Activating’ for enhancement of the effect of a gene product; ‘Loss of function’ for activity 
reduction or total inactivation of a gene product; ‘No class’ for unknown role of the alteration;
Activating
OncodriveROLE_prob Numeric Probability of the identified driver role; 0.877
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F. Copy Number Variations in Disease Data
The following table reflects the structure of the .txt filedata on CNVs associated with cancer downloaded from CNVD platform.
Column name Data type Description and comments on nomenclature Example
CNVD_ID Numeric Unique identifier according to the CNVD standard; 302652
Species Factor The organism in the study; Homo sapiens
Chromosome Factor Chromosomal localization of CNV; 16
Start_Position Numeric Coordinates of the CNV’s start; 88280576
End_Position Numeric Coordinates of the CNV’s stop; 88290263
Chr_region Factor Coordinates of the chromosome region with CNV; 16q24
Describe Factor Specification of the CNV type; Insertion
Gene Factor Genes encompassed by CNV, according to the HGNC nomenclature; CDK10
Disease Factor Disease associated with CNV; Gastric cancer
Platform Factor Specification of the platform used in the study; Array CGH
Sample Factor Specifications on samples in study (number and type) 183 primary gastric cancer
quency Numeric Ratio of CNV observations among total number of samples; 0.18
PubMed_ID Numeric Study reference; According to PUBMED annotation; 24379144
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Appendix 2
Selected Features
This appendix provides an list of genes selected with a developed workflow using the Lasso algorithm.
Instances are ordered according to the frequency of occurance, starting from the most recurrent.
List of Genes:
ATR
EGFR
DUSP5
PIP5K1A
TTC40
BIRC2
LOC100507266
GSTT1
LRRC4
TNFAIP8L3
MAP2K7
SKAP1
MAP2K1
XIAP
LRP1B
C7orf54
NCKAP5
PNPLA7
PSG4
SEC61G
ACOXL
SAGE1
CES1P1
CIR1
NKAIN4
TPRX1
WNT7A
ABCA10
ASB5
CCDC129
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CCDC129ENST00000451887
RHAG
SPNS3
C20orf85
DDX25
GALNTL2
MAP2K2
PGA3
PTK2
ZNF99
TRIM54
PTGIS
SOCS3
SOLH
STOML1
MYOFENST00000371501
SCYL1ENST00000270176
TMEM119
VPS25
ADAMTS16
CERKL
ELK2AP
LOC283922
MAP3K15
MMP1
PGA4
RRM1
ZNF623
LPIN2
PDRG1
TEK
PTK2B
TPTE2P6
EPS15
MINOS1
TMEM130
EPHA5
FGFBP2
HLA.DPB1
HTR7ENST00000371721
SCYL1
TMPRSS15
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